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Abstract 
Isometric handgrip (IHG) training lowers resting blood pressure (BP), but the high cost of 
traditional computerized IHG devices can be a barrier to use. Inexpensive mechanical IHG 
devices could address the cost barrier, but the acute stimulus of such devices must be 
determined. This study compared changes in systolic and diastolic BP, heart rate (HR), muscular 
activation, ratings of perceived exertion (RPE), and pain between a computerized and a 
mechanical IHG device during an IHG bout. Twenty healthy adults (X ± SD; Age: 22.4 ± 2.2 
yrs.; ♀= 9; BP: 114/64 ± 11/7 mmHg) randomly performed an IHG bout (4, 2-min IHG 
contractions at 30% of maximum voluntary contraction, separated by 4-mins rest) on each 
device. BP, HR, and forearm surface EMG data of the non-dominant arm were collected 
throughout. RPE and pain were acquired at the end of each contraction. 
SBP, HR, RPE and NRS-Pain scores did not differ between devices (p > 0.05)> 
However, statistically significant differences in DBP were observed (p < 0.05), whereby the 
computerized device elicited a higher DBP response than did the mechanical device. 
Furthermore, significant elevations in muscular activation for only the biceps brachii and 
extensor carpi ulnaris were observed in the mechanical handgrip device (p < 0.05). 
The mechanical IHG induced similar acute SBP, HR, RPE and NRS-pain scores as well as 
similar muscular activation for 3 of the 5 muscles tested as the traditional computerized device. 
These findings suggest that perhaps this inexpensive alternative device could be a feasible 
equivalent to the traditional computerized device during acute exercise. Future studies should 
examine whether this inexpensive handgrip device can elicit similar training-induced reductions 
in resting BP as with the traditional computerized devices.  
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1.1 Cardiovascular Disease 
 Non-communicable diseases, such as cardiovascular disease (CVD), are now the main cause 
of mortality worldwide (WHO 2013). CVD is an umbrella term for a group of diseases that 
include coronary heart disease, cerebrovascular disease, hypertension (HTN), peripheral vascular 
disease, heart failure, rheumatic heart disease, congenital heart disease and cardiomyopathies 
(WHO, 2013). CVD is the leading cause of death globally (WHO, 2013).   
In 2008, CVD contributed to nearly 17.3 million deaths worldwide and is projected to reach 
23.6 million deaths by the year 2030 (WHO, 2013). Nationally, nearly 62 thousand deaths/year 
were considered CVD-related in 2012 (Statistics Canada, 2015). More locally, CVD contributes 
to the deaths of nearly 1225 residents of Windsor-Essex County each year (Windsor-Essex 
County Health Unit, 2015).  
Fortunately, advances in modern medicine have extended the lives of individuals with CVD 
through effective disease management and treatment. However, CVD places a substantial 
financial burden on the economy. In Canada, CVD was responsible for $20.9 billion dollars in 
direct and indirect health care expenses such as hospitalization, lost wages and disability in 2008, 
and healthcare-related expenses are expected to reach nearly $28.3 billion by the year 2020 
(Theriault et al., 2010). Accordingly, the World Health Organization (WHO) deems CVD a 
global health crisis, and places an importance on primary prevention (WHO, 2013). The WHO 
recommends the adoption of a healthy lifestyle including the limitation of alcohol and tobacco 
consumption, adopting healthy dietary habits, lowering sodium intake, increasing physical 
activity, maintaining a healthy bodyweight and lowering high cholesterol (WHO, 2013). 
Recognizing the importance of preventing the progression of CVD, the government of Ontario 
has provided funding to programs such as the Cardiac Care Network of Ontario (CCN), one of 
the largest programs in North America devoted to enhancing quality, efficiency and access of 
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cardiovascular services in Ontario (CCN, 2017). Additionally, the Hypertension Management 
Program (HMP), was created to improve detection, diagnosis, treatment and prevention of HTN 
(Ontario Stroke Network, 2015). 
1.2 Hypertension 
1.2.1 Defining Hypertension 
 Hypertension (HTN) or chronic elevations in resting and/or ambulatory arterial blood 
pressure (BP), is both a type of CVD and the leading modifiable risk factor for CVD (WHO, 
2013). Arterial BP is represented by two measurements: systolic BP (SBP) representing the 
pressure exerted onto the arterial walls when the ventricle contracts during the cardiac cycle, and 
diastolic BP (DBP) representing the pressure exerted onto the arterial walls during the portion of 
the cardiac cycle where the ventricles are relaxing, and the atria are filling (Herd, 1970).  
 Normal BP is indicated by a mean resting SBP of <120 mmHg and DBP of <80 mmHg 
(Nerenberg et al., 2018; Whelton et al., 2017; Heart and Stroke, 2017). Furthermore, measures 
between 120-129 mmHg SBP and or values >80 mmHg DBP are considered to be elevated or 
“pre-hypertensive” (Pre-HTN) (Whelton et al., 2017; Heart and Stroke; 2017; Guo et al., 2011). 
Pre-HTN individuals have been shown to be at greater risk of developing CVD than those with 
lower BP (Guo et al., 2011). Currently, HTN is classified as resting office SBP of >130 mmHg, a 
DBP >80 mm and/or prescribed anti-hypertensive medication (see below: Section 1.2.4; Whelton 
et al., 2017; Myers et al., 2015). Furthermore, individuals can be diagnosed as having HTN by 
using ambulatory blood pressure monitoring (ABPM) devices if they have day time BP values 
>135/85 mmHg, a nighttime BP >120/80 mmHg or a 24-hour average BP >130/ 80 mmHg 
(Nerenberg et al., 2018). HTN is further categorized into stages depending on whether a 
particular threshold of BP is reached. Traditionally, HTN has been defined as Stage 1 HTN as 
140-159/90-99 mmHg and Stage 2 HTN as >160/100 mmHg (Nerenberg et al., 2018). Recent 
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Canadian and American guidelines endorse more conservative stages, with Canada identifying 
Stage 1 HTN as those individuals with arterial BP of 135-139/85-89 mmHg, and Stage 2 HTN as 
those with arterial BP of >140/90 mmHg (Nerenberg et al., 2018). The American guidelines 
offer even more conservative staging, with elevated BP ranging from 120-129/ <80 mmHg, 
Stage 1 HTN between 130-139/80-89 mmHg, and Stage 2 HTN ≥140/ ≥90 mmHg, Whelton et 
al., 2017).  Furthermore, a diagnosis of hypertensive urgency HTN can be given if an individual 
has a BP exceeding 180/120 mmHg (Whelton et al., 2017). Finally, a diagnosis of hypertensive 
emergency can be given if the BP exceeds 180/120 mmHg and includes the presence of target 
organ damage (Whelton et al., 2017). 
With advancements in BP measurement technology (see Section 1.2.4), HTN can now be 
more accurately diagnosed. For instance, AOBP devices provide more accurate representations 
of BP compared with traditional manual measurements and allow for a diagnosis of HTN to be 
made if an individual has a resting BP >135/85 mmHg (Myers et al., 2010; Nerenberg et al., 
2018). New research suggests that the superior method for determining BP is through the use of 
ambulatory BP monitoring (ABPM), which provides insight into BP fluctuations over a 24-hour 
duration (Pickering et al., 2006). Individuals can be diagnosed as having HTN using ABPM 
devices if they have day time BP values >135/85 mmHg, a night time BP >120/80 mmHg or a 
24-hour average BP >130/80 mmHg (Nerenberg et al., 2018). 
 HTN can also be categorized based on the origin of the elevations in BP as either primary 
(essential) or secondary HTN. Secondary HTN is characterized by elevations in BP that can be 
directly attributed to another disease such as renal failure, renovascular disease, aldosteronism 
and pheochromocytoma and accounts for only 5% of all HTN cases (Gupta-Malhotra et al., 
2014; Carretero et al., 2000). Alternatively, primary or essential HTN has no direct cause that 
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can be identified but is suspected to be linked to numerous factors such as having a genetic 
predisposition to HTN as well as lifestyle factors such as sedentary behavior, alcohol and 
tobacco use, a nutritionally deficient diet, high stress and obesity (Gupta-Malhotra et al., 2014; 
Carretero et al., 2000). Unfortunately, primary HTN makes up 95% of all HTN cases (Gupta-
Malhotra et al., 2014; Carretero et al., 2000). Consequently, prevention of HTN should be 
targeted through the modification of the lifestyle factors listed above (WHO, 2013).  
1.2.2 Prevalence of Hypertension 
Of the 17.2 million CVD-related deaths in Canada in 2012, 9.4 million of these are the 
result of BP-related complications due to HTN (WHO, 2013). The worldwide prevalence of 
HTN is steadily rising; in 2000, nearly 600 million people were diagnosed with HTN and this 
number rose to 1 billion by the year 2010 (Mills et al., 2016). In Canada, nearly 5.3 million 
Canadians were diagnosed with HTN in 2014, which equates to about 1 in every 5 Canadians as 
having HTN (Statistics Canada, 2016). More locally, 19% of people ages 12 years and older are 
diagnosed with HTN in Windsor-Essex County, which equated to nearly 74 000 people in 2011 
(Windsor-Essex County Health Unit, 2014). Therefore, immediate action must be taken in 
primary prevention and disease management to prevent the growing rates of both HTN and 
CVD. 
 1.2.3 Blood Pressure Regulation 
 BP regulation is a key modulator of adequate perfusion of body tissues (Herd, 1970). BP 
is controlled through manipulations of cardiac output (Q) and total peripheral resistance (TPR; 
Raven & Chapleau, 2014). Q is the product of stroke volume (SV), and heart rate (HR; Raven & 
Chapleau, 2014), while TPR refers to the amount of resistance to blood flow that is exerted by 
the systemic blood vessels through arterial diameter manipulations known as vasoconstriction 
(reduced arterial diameter) and vasodilation (augmented arterial diameter; Ackerman, 2004). SV 
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represents the amount of blood that is pumped from the heart per beat, whereas HR refers to the 
number of heart beats per minute (Raven & Chapleau, 2014). Therefore, BP is altered by 
perturbations in Q via increases or decreases in HR and/or SV, and through manipulations of 
TPR via changes to arterial diameter. This process of BP modulation is controlled through the 
interaction of intrinsic neurological, hormonal and local arterial mechanisms.  
1.2.3.1 Neurological Regulation of Blood Pressure 
 BP is centrally regulated by the autonomic nervous system (ANS) and its two branches: 
the sympathetic nervous system (SNS) and the parasympathetic nervous system (PNS) 
(Dampney et al., 2002). SNS stimulation increases the excitation of contractile neurons in the 
heart, which increases HR, alters Q, and results in a rise of BP (Dampney et al., 2002). The SNS 
can also cause vasoconstriction, subsequently increasing TPR and BP (Dampney et al., 2002). 
Alternatively, the PNS lowers BP by stimulating the vagus nerve which innervates the heart 
(Pavlov & Tracey, 2012). Vagus nerve stimulation activates the muscarinic receptors (see 
Section 1.2.3.2) responsible for the lowering of HR and decreasing myocardial excitability 
(Pavlov & Tracey, 2012; Dampney et al., 2002). Optimal BP is maintained through balancing the 
stimulation of the SNS and PNS.  
The activity of the PNS and SNS is regulated by two higher control centres in the brain: 
the central command (CC) and the cardiovascular control centre (CCC) (Nobrega et al., 2014). 
The CC senses and regulates ANS activity via stimulation of the CCC (feed-forward control) that 
innervates the heart and blood vessels, which can result in either SNS or PNS stimulation to 
increase or decrease BP, respectively (Nobrega et al., 2014).  Additionally, this system also has 
innate negative feedback control through receptors located in the periphery known as arterial 
baroreceptors, chemoreceptors, and muscle afferent receptors. These receptors all provide 
feedback to the CCC to maintain a particular BP “set point” (Nobrega et al., 2014).  
 7 
 
Arterial baroreceptors are sensitive to tensile changes in the carotid arteries, pulmonary 
vessels, and aorta (Lafranchi & Somers, 2002). When BP is increased above a certain set point, 
this causes pressure to be placed on the walls of the blood vessel, resulting in stretching of the 
arterial walls (Papaioannou, 2007). Baroreceptors detect this stretching and trigger afferent 
signalling to the CCC, which in turn decreases SNS stimulation, HR, cardiac contractility and 
TPR (Papaioannou, 2007). Alternatively, if BP drops below the set point, a decrease in tension 
against the vessel walls triggers afferent signalling from the baroreceptors to the CCC 
(Papaioannou, 2007). These signals reduce PNS and increase SNS signalling to increase HR, 
cardiac excitability, and TPR in order to raise BP back to the homeostatic set point 
(Papaioannou, 2007; Lafranchi & Somers, 2002). 
Chemoreceptors, located in the carotid and aortic arteries, are responsible for detecting 
perturbations of the partial pressures of oxygen (PaO2), carbon dioxide (PaCO2), and hydrogen 
ion concentrations ([H+]) that are produced as a result of increased cellular respiration (Moreira 
et al., 2011).  Under low oxygen states, such as during moderate to vigorous aerobic exercise, 
chemoreceptors detect a decrease in [PaO2] in addition to an increase in [PaCO2] and [H
+], which 
triggers afferent signalling to the CCC to stimulate SNS activity (Moreira et al., 2011). This 
stimulation of the SNS raises HR, Q and TPR, which increases BP and stimulates ventilation for 
the purposes of adequate tissue perfusion of oxygen (Moreira et al., 2011).   
 The final periphery receptors involved in the feedback control between the CC and CCC 
are the muscle afferent receptors. There are two types of muscle afferent receptors that regulate 
BP homeostasis: type III afferent mechanoreceptors and type IV metaboreceptors (Leshnower et 
al., 2001). Similar to arterial baroreceptors, the main function of the type III afferent 
mechanoreceptors is to sense stretch and pressure differences within the arteries that occur 
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during muscular contraction (Leshnower et al., 2001). When stimulated, type III afferent 
mechanoreceptors relay this information back to the CCC, influencing SNS stimulation and PNS 
inhibition, which raises Q through increases in HR and subsequently raises BP (McCord & 
Kaufman, 2010). Although mechanoreceptors and metaboreceptors serve a similar purpose (alter 
BP in response to physical demands such as exercise), type IV afferent metaboreceptors differ in 
terms of the stimuli to which they are sensitive. Metaboreceptors are receptors that are sensitive 
to increases in the concentration of by-products of metabolism, which include lactic acid, 
potassium (K+), deprotonated phosphate, serotonin, bradykinin and adenosine (McCord & 
Kaufman, 2010). When elevated concentrations of metabolites are detected, the metaboreceptors 
relay this information to the CCC, which augments SNS activity, reduces PNS stimulation and 
increases Q, HR, and TPR, ultimately increasing BP to clear these metabolic by-products from 
metabolically active tissue (McCord & Kaufman, 2010). This increase in BP allows for greater 
perfusion of blood to the active muscle, thus delivering more O2 to active tissues and facilitating 
the disposal of accumulated metabolites (McCord & Kaufman, 2010). Mechanoreceptors and 
metaboreceptors ultimately work synergistically to accommodate for normal hemodynamics 
during exercise (McCord & Kaufman, 2010).  
1.2.3.2 Hormonal Regulation of Blood Pressure 
 Changes in BP can also be regulated via the neuroendocrine system through coordinated 
actions of hormones (Gordon et al., 2015). The hormones influencing BP include the 
catecholamines epinephrine (E) and norepinephrine (NE), acetylcholine (ACh), angiotensin, 
aldosterone, arginine vasopressin (AVP) and atrial natriuretic peptide (ANP). 
 The ANS is regulated by preganglionic and postganglionic neurons that secrete 
neurotransmitters at the synaptic clefts to transfer signals across the axons (Thomas, 2011). The 
neurotransmitter ACh is released between the preganglionic and postganglionic neurons in both 
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the SNS and PNS, however the SNS releases NE via postganglionic neurons at the synaptic cleft, 
whereas the PNS releases ACh (Gordan et al., 2015). Both E and NE are secreted by the adrenal 
medullary cells via stimulation of sympathetic innervation (Thomas, 2011). The function of E 
and NE is mainly dependent on the type and location of the receptor to which they bind 
(Guimaraes & Moura, 2011). There are two main types of receptors: α-adrenergic and β-
adrenergic (Guimaraes & Moura, 2001). The α1-adrenergic receptors are found in most vascular 
smooth muscle of sympathetic target organs (excluding the heart), while the α2-adrenergic 
receptors are located near the synaptic junction of SNS nerve cells of vascular beds (Guimaraes 
& Moura, 2001). Activation of both types of α-adrenergic receptors elicit vasoconstriction 
(Thomas, 2011). β1-adrenergic receptors are found in the heart, kidneys, lungs, and adipose 
tissue, whereas β2-adrenergic receptors are found in most SNS target organs such as the heart, 
eyes, kidney, brain, gastrointestinal tract, and vascular smooth muscle (Guimaraes & Moura, 
2001; Gordon et al., 2015). Stimulation of β1-adrenergic receptors by E or NE leads to increases 
in HR and myocardial contractility, as well as triggering the kidneys to release renin to increase 
vasoconstriction and ultimately BP (Gordon et al., 2015). β2-adrenergic receptor activation 
causes vasodilation of SNS target organs such as the heart, liver and skeletal muscles in order to 
increase blood perfusion to metabolically active tissue (Guimaraes & Moura, 2001). The 
activation of α-adrenergic and β-adrenergic receptors causes changes in smooth muscle diameter 
via vasoconstriction and vasodilation, ultimately resulting in the regulation of BP from changes 
in TPR (Furchgott, 1983). 
Alternatively, the PNS is regulated by the release of ACh at the synaptic junction of 
parasympathetic nerve cells (Gordon et al., 2015). The binding of ACh occurs on two types of 
muscarinic receptors known as M2 and M3 receptors (Gordon et al., 2015). M2 muscarinic 
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receptors are found in abundance in cardiac muscle cells. ACh binding triggers M2 receptor 
activation, resulting in decreasing depolarization through perturbations in conduction velocity 
across the atrioventricular node (Gordon et al., 2015). This works to synergistically promote 
normal hemodynamics through a decreased cardiac contractility through a reduction in HR, 
subsequently leading to decreases in Q and BP (Gordon et al., 2015; Mysliveček & Trojan, 
2003). M3 receptor activation facilitates the release of nitric oxide (NO) from the endothelium 
which causes vascular vasodilation and a decrease in BP (see Section 1.2.3.3; Brodde & Michel, 
1999).  
 The renin-angiotensin-aldosterone system (RAAS) works to regulate BP through its 
influence on vascular tone and blood volume (Nguyen et al., 2002). Reductions in blood volume 
triggers the release of the glycoprotein renin from the kidneys, which converts the non-active 
pro-hormone angiotensinogen into angiotensin I (Nguyen et al., 2002). Angiotensin I is further 
modified by angiotensin converting enzyme (ACE) into angiotensin II, the active form of the 
hormone (Nguyen et al., 2002). Angiotensin II is a powerful vasoconstrictor that increases BP 
through increases in TPR (Nguyen et al., 2002). Decreases in blood fluid volume also trigger the 
release of a hormone known as aldosterone from the adrenal cortex, which stimulates fluid 
retention through conservation of sodium (Granger & Schnackenberg, 2000). This process 
increases the blood fluid volume, which raises SV and increases BP via increases in Q (Weir & 
Dzau, 1999; Hall et al., 1990). 
AVP, also known as antidiuretic hormone, is secreted by the posterior pituitary in 
response to decreases in blood fluid balance and acts as a powerful vasoconstrictor that increases 
BP by augmenting TPR (Henderson & Bryon, 2007; Nguyen et al., 2002). AVP works 
particularly well at stimulating vasoconstriction in skin, muscle, and visceral arterial beds 
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(Henderson & Bryon, 2007). AVP also stimulates the release of aldosterone, which causes an 
increase in blood volume, SV, and BP (Granger & Schnackenberg, 2000; Hall et al., 1990). 
 ANP is a hormone secreted by the atria in response to increased stretching of the atrial 
vessel walls in the heart (Venugopal, 2001). Release of ANP is related to increased sympathetic 
activation (Ruskoaho, 2011). Therefore, ANP lowers BP by inhibiting actin-myosin binding of 
cardiac vessel smooth muscle, which inhibits vasoconstriction of the blood vessels and lowers 
TPR (Münzel et al., 2003). ANP can also control BP through decreases in blood volume. Release 
of ANP triggers the kidneys to expel both water and sodium, leading to decreases in Q through a 
smaller SV, ultimately reducing BP (Venugopal, 2001).  
1.2.3.3 Local Blood Pressure Control 
 BP is regulated through locally secreted substances in the peripheral vasculature that are 
produced in response to metabolic demands of tissues. These locally released substances include 
NO, endothelin-1 (ET-1), K+, and adenosine derivatives; they work by modifying BP through 
changes in TPR via alteration of the diameter of smooth muscle vasculature (Webb, 2003). 
 The increase in blood flow to muscles is associated with an increased metabolism, which 
elicits a rise in the amount of vascular pressure or “shear stress” exerted against the most inner 
layer of the blood vessel known as the endothelium (Furchgott, 1983). This increase in 
endothelial pressure triggers the release of a potent vasodilatory compound known as NO 
(Furchgott, 1983). NO is derived from the amino acid L-arginine by the enzyme NO synthase 
(Thijseen et al., 2011). NO then diffuses out of the endothelium where it can react with 
vasculature smooth muscle to increase arterial diameter, reducing TPR and thus lowering BP 
(Paniagua et al. 2001).   
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 ET-1, a vasoconstrictor, is a regulatory mechanism for BP that counters the localized NO, 
as previously noted. ET-1 production is activated by endothelial chemicals (AVP and NE) and 
mechanical (shear stress) stimulation (Agapitov & Haynes, 2002). The action of ET-1 is entirely 
dependent on which type of ET-1 receptor is activated. Upon activation, ETB2 and ETA receptors 
trigger vasoconstriction of vascular smooth muscle, thus increasing TPR and raising BP (Gordon 
et al., 2015). Alternatively, ETB receptor activation causes NO release from the endothelium due 
to increases in shear stress, triggering vascular smooth muscle relaxation (vasodilation), resulting 
in decreased TPR and ultimately lowering BP (Agapitov & Haynes, 2002). 
 K+ is another key player in localized BP regulation (Haddy et al., 2006). During muscular 
contractions, K+ is released from the endothelium due to sheer stress and accumulates in the 
intracellular space of vascular smooth muscle membranes (Haddy et al., 2006). This 
accumulation of K+ stimulates the Na+/K+ pump to hyperpolarize the cell, which in turn inhibits 
the influx of Ca+ (Haddy et al., 2006). This decrease in intracellular Ca+ inhibits the ability of 
vascular smooth muscle to contract, which lowers TPR, and thus decreases BP (Haddy et al., 
2006). 
Adenosine triphosphate (ATP), an adenosine derivative, is an important substrate for 
muscular contraction (Marshall, 2007). Utilization of ATP in muscular contraction elicits the 
accumulation of ATP by-products, such as adenosine diphosphate (ADP), adenosine 
monophosphate (AMP), and adenosine (Haddy & Scott, 1968). As ATP concentrations decrease 
and the concentration of other adenosine metabolites increase, these metabolites activate 
adenosine receptors on the endothelium known as A1, A2A or A2B receptors (Marshall, 2007). 
Activation of these receptors generates a vasodilatory effect on smooth muscle, which increases 
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the arterial diameter to augment blood flow to the working muscles in order to combat the 
metabolic demand (Marshall, 2007). This vasodilation decreases TPR, and thus lowers BP. 
1.2.4 Blood Pressure Measurement 
 BP measuring techniques range in level of invasiveness and accuracy. Currently, the most 
accurate method of BP measurement involves the implantation of a catheter into the radial artery 
(Balaji & Shah, 2011). Beat-to-beat SBP, DBP and mean arterial pressure (MAP; [systolic BP + 
2(diastolic BP)] / 3) are derived from a pressure transducer attached to the catheter, which is 
inserted into the brachial artery through the wrist (Balaji & Shah, 2011). Although this method is 
classified as the gold standard in BP measurement, due to the higher costs, invasiveness and 
expertise required to administer the catheter, it is not used as a practical BP measurement 
modality by most clinicians (Balaji & Shah, 2011). Currently, clinicians can implement less 
invasive, time- and cost-effective measurement tools for BP like auscultatory 
sphygmomanometry and oscillometry (Pickering et al., 2005). Both techniques are non-invasive 
and obtain measures at the level of the brachial artery (Pickering et al., 2005). Non-invasive 
forms of BP monitoring provide similar accuracy to invasive techniques (Bing et al., 2014). 
Furthermore, there is growing clinical interest regarding a novel form of oscillometry known as 
“ambulatory BP monitoring”. Ambulatory BP monitoring allows for BP measurement over a 24-
hour duration and evidence suggests it is a better prognostic indicator of CVD compared to 
office BP measurement (Sherwood et al., 2012). 
1.2.4.1 Auscultatory Sphygmomanometry 
 A non-invasive technique known as auscultatory sphygmomanometry is performed by 
utilizing an inflatable cuff and sphygmomanometer to determine BP (Beevers et al., 2001). BP is 
determined through the timing of audible sounds produced as blood flow causes oscillations 
inside arterial walls known as “Korotkoff sounds” (Beevers et al., 2001). This technique is 
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employed when assessing “office BP” (OBP; Nerenberg et al., 2018). An inflatable cuff is placed 
around the patient’s arm and inflated to a point at which no Korotkoff sounds are heard due to 
occlusion of blood flow (>SBP; Pickering et al., 2005). A stethoscope is then placed at the point 
of radial pulsation (Beevers et al., 2001). The cuff is gradually deflated and the examiner listens 
for the onset and absence of the Korotkoff sounds (Beevers et al., 2001). The Korotkoff sounds 
can be categorized into 5 phases: the 1st phase is categorized by the first presence of Korotkoff 
sounds and represents SBP, while the 5th stage is when the audible sound is no longer heard and 
represents DBP (Pickering et al., 2005).  
Although this technique is non-invasive, and at one point was widely used among 
physicians, it has inherent limitations due to its dependence on the skill of the observer to 
interpret the exact onset and offset of the Korotkoff sounds (Pickering et al., 2005). Lack of 
concentration, poor hearing and confusion from visual or audible cues have been reported to 
cause error in BP measurement using this technique (Beevers et al., 2001). Furthermore, 
observer bias has been suggested to also be a limitation to this method, as the observer may 
already have a preconceived notion of what an individual’s BP may be based on their physical 
appearance, sex or age (Beevers et al., 2001). Observer bias may lead to an under-diagnosis of 
BP for younger healthy weight individuals and over-reporting BP for older or obese individuals 
(Beevers et al., 2001).  Another common limitation to using this technique occurs due to 
assignment of the wrong size cuffs for individuals (Manning et al., 1983). Using a cuff that is too 
big leads to an under-estimation of reported SBP and DBP values by 10-30 mmHg due to these 
cuffs requiring more pressure to occlude arterial blood flow (Manning et al., 1983). Due to these 
limitations, the auscultatory sphygmomanometry method could fail to diagnose or misdiagnose 
HTN (Pickering et al., 2005). 
 15 
 
1.2.4.2 Oscillometry 
Another non-invasive BP measurement technique using an inflatable cuff employs 
“oscillometry” to derive BP, and is used for AOBP measurement (Nerenberg et al., 2018). 
Unlike auscultatory sphygmomanometry, oscillometry does not rely on human interpretation of 
Korotkoff sounds, but instead measures BP via an electric pressure transducer (Stergiou et al., 
2011). As with auscultatory sphygmomanometry, a cuff is inflated over the arm until no 
oscillations are detected by a pressure transducer within the device (Ogedegbe & Pickering, 
2010; Berger, 2001). As the cuff is gradually deflated, the pressure transducer detects the point 
of maximal oscillation, which has been shown to correspond with MAP (Ogedegbe & Pickering, 
2010). The oscillometric device can then calculate SBP and DBP using algorithms (Pickering, 
2005). The main advantage to this technique over the auscultatory sphygmomanometer is that it 
prevents observer bias and error, as well as being less influenced by external noise (Stergiou et 
al., 2011). However, a notable limitation to this technique is that the oscillometric algorithms 
used to determine BP do not consider external factors influencing arterial BP like arterial 
stiffness, which can lead to errors in calculation of BP (Lui et al., 2013). It is also important to 
note that body position can influence BP measurement; participants should be seated with legs 
uncrossed and with the arm supported in a position that is approximately heart height (Pickering 
et al., 2005). Furthermore, it is important to ensure that the participant is fitted with an 
appropriately sized cuff, as cuffs that are too large or small have been shown to lead to 
inaccurate measurements of BP (Pickering et al., 2005). In addition, the algorithms used to 
derive BP are not standardized and vary depending on manufacturers, which could lead to 
potential discrepancies in BP values obtained between devices (Ogedegbe & Pickering, 2010). 
Despite these potential limitations, evidence supports oscillometry as providing reliable 
representation of BP, when compared to auscultatory sphygmomanometry (Stergiou et al., 2011). 
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1.2.4.3 Ambulatory Blood Pressure  
 ABPM is another oscillometric technique that involves acquiring BP measurements 
across a 24-hour time span (O’Brien et al., 2013). Unlike other oscillometric devices, the 
inflatable hose is attached to a portable monitor, which allows individuals to have BP 
measurements taken in non-clinical settings that may more accurately represent BP (O’Brien et 
al., 2013). The ABPM device is programed to take BP measurements every 30 minutes, with 
some protocols even utilizing BP measurement every 15 or 20 minutes (O’Brien et al., 2013; 
Pickering et al., 2006). The data from the ABPM device are transferred to a computer where a 
mean daytime, nighttime and 24-hour BP values can be determined (O’Brien et al., 2013; 
Pickering et al., 2006).  
 The main advantage of using ABPM is that its portability allows BP to be measured in 
non-clinical settings and prevents the phenomenon known as “white coat hypertension” (O’Brien 
et al., 2013, Franklin et al., 2013). White coat HTN is defined as BP measurements within the 
HTN range when BP is examined in a clinical setting, but values fall within the normal range 
when BP is taken at home or a non-clinical setting (Franklin et al., 2013). White coat HTN is 
suggested to be caused by anxiety in a clinical setting and is particularly prevalent in women, 
older adults and those recently diagnosed as having HTN (Franklin et al., 2013). ABPM can be 
used to rule out white coat HTN, and therefore, prevent misdiagnosis of HTN, and potentially 
limit unnecessary treatment of non-hypertensive individuals (i.e., being prescribed anti-
hypertensive medications) (Lovibond et al., 2011). 
 In healthy individuals, SBP and DBP decreases or “dips” at least 10% during sleep; these 
individuals have been classified as “normal dippers” (Birkenhäger & van den Meiracker 2007; 
Mahabala et al., 2013). ABPM can be used to assess cardiovascular risk by measuring BP 
throughout the sleep cycle to determine whether an individual expresses normal dipping of BP 
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(>10% reduction in BP), or has reductions <10%, which would classify them as a non-dipper 
(Birkenhäger & van den Meiracker 2007; Mahabala et al., 2013). Furthermore, dipping >20% 
would classify an individual as an excessive dipper (Kazuomi et al., 1996). Evidence supports 
that non-dipping and excessive dipping are correlated to increased cardiovascular risk, such as 
increased arterial stiffness, cardiac organ damage, diabetic retinopathy, impaired glucose 
tolerance and increased risk of CVD development (Hermda et al., 2013; Birkenhäger & van den 
Meiracker 2007; Dela Mea et al., 2005; Kazuomi et al., 1996). Additionally, ABPM has been 
shown to be a better predictor of CVD-related mortality and morbidity in women than men 
(Boggia et al., 2011). Therefore, ABPM is a useful tool for both the diagnosis of HTN, and the 
determination of CVD risk for individuals diagnosed with HTN. 
1.2.5 Pathophysiology of Hypertension 
 Although the direct mechanism of primary HTN development is not entirely understood, 
evidence supports the idea of pathologically high BP resulting from perturbations to neural, 
hormonal and/or local homeostatic mechanisms (Bakris & Mensah, 2002).  
The ANS plays a key role in BP maintenance. In the case of HTN, evidence suggests that 
overstimulation of the SNS leads to increases in BP through unusually high concentrations of 
circulating adrenergic neurotransmitters (NE and E) in hypertensive individuals (Mancia & 
Grassi, 2014; Ferrier et al., 1993). This increase in stimulation of sympathetic nerves and leads to 
increases in Q due to elevated HR and fluid retention that will ultimately increase BP (Parati & 
Esler, 2012). Along with SNS overstimulation, under-activation of the PNS is observed in 
hypertensive individuals, which leads to reduced vagus nerve inhibition of HR (Mancia & 
Grassi, 2014). This combined overstimulation of the SNS and under-activation of the PNS leads 
to increases in Q and ultimately BP (Olshansky et al., 2008).  
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In the case of HTN, chronic elevations in BP lead to structural remodelling of the arterial 
walls, which may ultimately cause the stiffening of cardiac and peripheral blood vessels (Mayet 
& Hughes, 2003). Recall that baroreceptors located in the carotid, pulmonary and aortic blood 
vessels detect mechanical stretching of the vessel, and once a threshold of stretch is detected, 
they will trigger CC signalling to shunt SNS activity and ultimately lower BP (Lafranchi & 
Somers, 2002). In the case of HTN, chronic elevations in BP cause vascular remodelling of the 
carotid arterial walls causing them to thicken and loose elasticity (Honzikova & Fiser, 2009). 
Thus, baroreceptors lose sensitivity and become less able to detect stretching of the carotid 
arteries, which can lead to chronically increased BP (Honzikova & Fiser, 2009). This effect of 
baroreceptor insensitivity is supported through research showing that individuals with 
chronically high BP have decreased baroreceptor function, compared to individuals with normal 
BP (Mussalo et al., 2002).  
 In regard to the RAAS system, the increased SNS activation discussed above leads to 
elevations in circulating renin and angiotensin II, leading to increased fluid retention and 
vasoconstriction, ultimately increasing BP (Manrique et al., 2009). There is growing evidence to 
support that this increase in RAAS activity negatively affects vasculature structure remodelling, 
which contributes to systemic stiffening of the arteries and cardiac and peripheral blood vessels, 
which increases TPR, BP and lowers baroreceptor sensitivity (Pacurari et al., 2014). 
Additionally, in cases of endothelial dysfunction, production of vasoconstrictor ET-1 is up-
regulated and NO is down-regulated (Hayes & Webb, 1998). This leads to localized 
vasoconstriction and impaired vasodilation, which increases TPR, and in turn, BP (Hayes & 
Webb, 1998). There is evidence to show that hypertensive individuals display higher 
concentrations of ET-1, compared to a normotensive control group (Shichiri et al., 1990). This 
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elevation in ET-1, together with limited NO production, leads to impaired local control of 
vasculature, which increases TPR and ultimately BP (Dharmashankar & Widlansky, 2010). 
There are numerous lifestyle factors that are thought to contribute to chronic elevations in 
BP.  Excessively high sodium intakes, lack of physical activity, high psychological stress, 
smoking, diet lacking in fruits, vegetables, magnesium, Ca+ and K+ have been shown to increase 
the development of HTN (Nerenberg et al., 2018; Frisoli et al., 2011).  
The risk of developing HTN also increases as a result of aging (Sun, 2015). For example, 
arterial stiffening throughout the aging process is suggested to be caused by a combination of 
metabolic syndrome, inflammation and dysfunction of neural hormonal pathways (i.e., increased 
SNS activity, aldosterone production and Na+ sensitivity), which all can contribute to 
endothelium dysfunction and increased arterial stiffness (Sun, 2015). Additionally, aging is 
associated with decreased baroreceptor function (Webber et al., 1989). Increased sodium 
retention, arterial stiffening and decreased baroreceptor function can all lead to increases in TPR 
(Sun 2015; Webber et al., 1989). This increase in TPR and Q leads to elevations in BP in elderly 
individuals (Sun, 2015; Webber et al., 1989).  
Sex differences occur in BP regulation.  A meta-analysis examining resting BP across the 
sexes found that up to menopause, women have significantly lower BP compared to men aged 
18-39 years (Sandberg & Ji, 2012). Furthermore, white non-Hispanic women aged 50-69 years 
still had lower BP than men, but sex differences became less apparent for this age cohort for non-
Hispanic black and Mexican American individuals (Sandberg & Ji, 2012). Concernedly, women 
over the age of 70 years had higher instances of HTN than men of the same age (Sandberg & Ji, 
2012). Although the exact mechanisms of why pre-menopausal women have lower BP compared 
to men requires further investigation, evidence suggests that estrogen elicits protective 
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cardiovascular effects in women that contribute to better endothelial function, and consequently, 
reduced TPR and BP (Murphy & Kelley, 2011).  
Finally, there are racial and ethnic differences in BP. In 2006, Wang and colleagues 
examined the differences in ambulatory BP of European Americans and African Americans from 
childhood to early adulthood and found that African American individuals had higher day-time 
and night-time ambulatory mean SBP and DBP compared to European Americans (Wang et al., 
2006). Furthermore, African Americans showed significantly less night-time BP dipping than the 
European Americans, which was further exasperated as the participants aged (Wang et al., 2006). 
As discussed in the ABPM section above, non-dipping is associated with increased risk of CVD 
(see Section 1.2.3 Blood Pressure Measurement). Findings from Wang and colleagues (2006) 
would suggest that African American individuals are at increased risk of developing CVD and 
other HTN-related complications, such as organ damage, compared to their European American 
counterparts (Wang et al., 2006; Sega et al., 2002). 
1.2.6 Hypertension Treatment and Management  
 Ultimately, the aim of HTN management is to lower elevated BP into ideal clinical 
ranges (Pescatello et al., 2015). Currently, the Canadian Hypertension Education Plan 
recommendation is for hypertensive individuals to reduce SBP <135 mmHg and DBP <85mmHg 
obtained through AOBP devices (Nerenberg et al., 2018). Interestingly, the American guidelines 
have made new recommendations to reduce BP below SBP <120 mmHg and DBP <80 mmHg, 
showing that the recommendation in this field are continually changing (Whelton et al., 2017). 
Additionally, individuals who are at high risk of developing CVD (without diabetes or stroke) 
require more intensive reduction in SBP of <120 mmHg to reduce risk of CVD development 
(Nerenberg et al., 2018). Additionally, it is recommended that Pre-HTN individuals reduce their 
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resting AOBP SBP to <120 mmHg and/or DBP <80 mmHg to prevent the advancement of HTN 
(Rosendorff et al., 2007). Elderly patients (>80 years of age) are recommended to lower SBP 
below 150 mmHg (Nerenberg et al., 2018). It is recommended to lower 24-hour ambulatory SBP 
and DBP to <130/80 mmHg, daytime ambulatory SBP and DBP to <135/85 mmHg, and night 
time SBP and DBP to < 120/70 mmHg, respectively (O’Brien et al., 2013). 
Recently, evidence from the SPRINT research group examining the effects of reducing 
BP of adults 50 years and older with SBP ranging from 130-180 mmHg to either <120 mmHg 
(intensive reduction group) or <140 mmHg (traditional reduction group), found that reducing 
SBP to below 120 mmHg resulted in fewer instances of fatal and nonfatal major cardiovascular 
events from any causes, compared to the <140 mmHg group (SPRINT research group; 2015).  A 
recent meta-analysis (123 studies comprised of 613 815 patients undergoing BP reducing trials) 
conducted by Ettehad and colleagues (2015) examined the effects of SBP reductions and its 
relation to the cases major cardiovascular events (Ettehad et al., 2015). Researchers found that 
every 10 mmHg reduction in SBP resulted in a proportional decrease in major CVD events, 
coronary heart disease, stroke, heart failure, and all-cause mortality (Ettehad et al., 2015). These 
studies provide support for the importance of lowering SBP in hypertensive individuals. 
 Currently, management of HTN is achieved through either lifestyle modification, and in 
many cases, the addition of pharmacotherapies (Nerenberg et al., 2018; Whelton et al., 2017). 
Adhering to proper dietary habits and engaging in regular exercise are key in the prevention and 
treatment of HTN (Nerenberg et al., 2018). Other recommendations for the management of BP 
are to limit alcohol consumption to <2 drinks per day, to maintain a healthy bodyweight, reduce 
stress, reduce sodium consumption and to cease smoking (Nerenberg et al., 2018). Dietary 
modifications targeting the management of HTN are summarized in the Dietary Approaches to 
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Stop Hypertension (DASH) diet, which emphasizes the consumption of fruits, vegetables, low-
fat dairy products, dietary fibre, whole grains, and protein from plant sources that is reduced in 
saturated fat and cholesterol (Nerenberg et al., 2018). Intervention studies implementing the 
DASH diet have been shown to produce reductions in both SBP and DBP (Moore et al., 2001; 
Sacks et al., 2001; Nerenberg et al., 2018). An accumulation of 60 to 150 minutes of aerobic 
exercise (intensity of 50-80% VO2max) a week that can be completed in 10-minute minimum 
bouts, is recommended for the management of healthy BP (Nerenberg et al., 2018; Whelton et 
al., 2017). Furthermore, 2-3 days of dynamic resistance exercise a week at an intensity of 60-
80% of a 1 repetition max (1RM) for 8-10 exercises (2-3 sets, 8-10 repetitions per set) is 
recommended as an adjunct to aerobic training (Nerenberg et al., 2018; Pescatello et al., 2015). 
Moreover, 4 × 2 min (hand grip), 1 minute of rest between exercises, 30%-40% maximum 
voluntary contraction (MVC) 3 times a week for 8-10 weeks is recommended in conjunction 
with aerobic exercise (Whelton et al., 2017). Unfortunately, if the lifestyle modifications listed 
above do not elicit adequate reductions in BP, pharmacotherapy is recommended to reduce BP to 
within the target clinical range (Whelton et al., 2017). Different classes of antihypertensive drugs 
can be implemented to control BP; commonly used medications are calcium channel blockers, 
angiotensin converting enzyme inhibitors, thiazide diuretics and beta-blockers (Whelton et al., 
2017). Calcium channel blockers work by inhibiting calcium uptake into the vascular smooth 
muscle, blocking calcium influx (which, as previously mentioned, promotes dilation), lowering 
TPR and ultimately BP (GodFraind, 2006). Angiotensin converting enzyme inhibitors prevent 
the conversion of angiotensin I to the vasoconstrictor angiotensin II, thus decreasing TPR and BP 
(Kalyesubula et al., 2014). Thiazide diuretics prevent Na+ reabsorption within the kidney (Duarte 
& Cooper-DeHoff, 2010). By reducing Na+ reabsorption, fluid volume is reduced via increased 
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urine expulsion, thus resulting in a lowered Q, and ultimately a reduced BP (Duarte & Cooper-
DeHoff, 2010). Although fluid volume is restored within 6 weeks of starting thiazide treatment, 
BP reductions are maintained, suggesting that chronic BP reductions are caused through a 
different mechanism or series of mechanisms, such as improved endothelium function or 
increased vasodilation, rather than solely fluid balance manipulation (Duarte & Cooper-DeHoff, 
2010). Finally, beta-blockers inhibit sympathetic stimulation of the heart by preventing the 
binding of NE and E, resulting in reduced HR, Q, and BP (Ram & Venkata 2010). 
 Although the lifestyle modifications listed above have been shown to be effective in the 
management of BP, only 15% of Canadians are meeting the recommendations of daily physical 
activity (Statistics Canada, 2014a), and only half of Canadians are consuming the recommended 
servings of fruits and vegetables (Statistics Canada, 2012). Furthermore, 15% of hypertensive 
Canadians have “uncontrolled” HTN, meaning that, although they are optimally treated, these 
individuals still have resting BP values exceeding 140/90 mmHg (Statistics Canada, 2014b).  
 Adherence to these lifestyle modifications (i.e., exercise and diet) appears to be difficult 
for some individuals due to perceived barriers such as time, energy, and for those with lower 
socio-economic status. Options for safe physical activity (i.e., public recreational facilities, bike 
paths, usable sidewalks, parks and social support), as well as access to healthy food and safe 
drinking water, may be difficult (Middleton et al., 2013; Tarasuk et al., 2013). There is growing 
concern for true “resistant” hypertensive individuals, who, despite being prescribed 3 or more 
antihypertensive medications and being compliant with lifestyle modifications, still display BP 
measurements above clinically recommended ranges (Calhoun et al., 2008). Poor adherence to 
pharmacotherapy, due to avoidance of unwanted side effects, has also been reported as a 
potential reason for BP measurements not meeting clinical targets (Svensson et al., 2000). These 
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findings argue that current HTN interventions are not effective for everyone, and therefore, novel 
interventions must be explored. 
1.3 Exercise Training  
Exercise training plays an important role in the management and treatment of HTN. 
Currently, the Canadian Physical Activity Guidelines recommend 150 minutes of cumulated 
moderate to vigorous aerobic physical activity a week completed in ~10 minute bouts for 
individuals over the age of 18 years (Tremblay et al., 2011). Furthermore, 2 or more days a week 
of bone and muscle strengthening exercise focusing on major muscle groups has been 
recommended to add additional benefit (Tremblay et al., 2011).  For hypertensive Canadians, 30-
60 minutes of moderate-vigorous dynamic physical activity (i.e., walking, jogging, cycling or 
swimming) 4-7 days a week, in addition to their routine activities of daily living, is 
recommended as a means of reducing BP (Nerenberg et al., 2018). Dynamic resistance exercise 
(free weight lifting, fixed weight lifting and handgrip exercise) has been recommended as an 
adjunct to aerobic exercise (Nerenberg et al., 2018). Moreover, isometric resistance exercise 
(IRE), specifically isometric handgrip (IHG) exercise, has also been endorsed by the American 
Heart Association and the Canadian Hypertension Education Program as an alternative exercise 
intervention to lower BP (Whelton et al., 2017; Nerenberg et al., 2018). Isometric exercise 
involves a sustained contraction against an immovable load with little to no alteration to 
muscular length (Inder et al., 2016). The most widely used IHG exercise protocol involves 4, 2-
minute isometric contractions at 30% of a maximum voluntary contraction (MVC) separated by 
a timed rest period, for a total duration of 12-15 minutes, completed at least 3 times a week for 8-
10 weeks (Whelton et al., 2017). IHG exercise and its effects will be discussed in greater detail 
below (see Section 1.4 Isometric Handgrip Exercise). 
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1.3.1 Acute Effects of Aerobic Exercise on Blood Pressure 
 Following the initiation of a bout of aerobic exercise, SBP and HR are increased via 
reduced parasympathetic outflow and increased sympathetic outflow that increases Q 6-10 fold, 
and in turn increases BP (MacDonald, 2002). This elevation in BP is further exasperated by 
vasoconstriction within venous vasculature to increase venous return and SV (MacDonald, 
2002). Furthermore, to match metabolic demand, blood flow is increased through vasodilation of 
arterioles that innervate more metabolically active tissues (i.e., skeletal muscle). In contrast, 
blood is shunted away from non-essential areas (i.e., digestive organs) via arteriole 
vasoconstriction. The increased vasodilation to working muscles serves as a buffer for the 
increase in BP achieved via augmented Q through reductions in TPR (MacDonald, 2002). The 
contracting muscles exert a substantial force onto the surrounding vasculature, and consequently, 
occlude blood flow (Delaney et al., 2010). As a result, metabolites such as K+, lactic acid, H+, 
and adenosine accumulate locally inside the exercising muscle tissue (Boushel, 2010). This 
increase in metabolic by-products leads to the activation of the exercise pressor reflex (EPR) 
(Delaney et al., 2010). The EPR sends afferent signals from the exercising muscles to the CC 
which evokes increased sympathetic activity that temporarily increases HR and BP in effort to 
restore perfusion of blood to working muscles (Delaney et al., 2010). The magnitude of the 
elevations in BP and HR are proportional to the length of time a muscle is contracted, the force 
at which the muscle is contracting, and the size of the active muscle (de Sousa et al., 2013; de 
Souza Nery et al., 2010; Rezk et al., 2006; MacDougall et al., 1985). Contraction of skeletal 
muscle also increases venous return of blood back to the heart and Q, resulting in increased BP 
(MacDonald, 2002). The decreased TPR noted above appears to have little effect on DBP during 
an acute bout of aerobic exercise, however, slight declines may occur due to blood flow 
increasing towards the periphery for heat dissipation (MacDonald, 2002).  
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 Following an acute bout of aerobic exercise, both SBP and DBP can be reduced, a 
phenomenon known as post-exercise hypotension (PEH). Although PEH has been shown to 
occur in both hypertensive and normotensive individuals, this effect seems to be more prominent 
for those with higher BP (Cardoso et al., 2010). Reductions in BP can occur within a magnitude 
of 2-12 mmHg over the course of 4-16 hours in HTN individuals (Cardoso et al., 2010). 
Evidence suggests that these findings are less pronounced in normotensive individuals, reporting 
smaller reductions of approximately 12 mmHg SBP and 5 mmHg DBP (Pardono et al., 2015). 
These findings support the idea that PEH reductions in BP are proportional to BP prior to 
exercise, so that higher pre-exercising BP values appear to have greater reductions following 
exercise than lower pre-exercising values (Cardoso et al., 2010). The exact mechanism causing 
PEH remains unknown, but reductions in TPR due to localized vasodilatory substances, as well 
as decreased sympathetic outflow, have been implicated (Cardoso et al., 2010; MacDonald, 
2002). 
 Acute aerobic exercise appears to have a lowering effect on ABPM in hypertensive 
populations (Ciolac et al., 2008; Cardoso et al., 2010). Following 40 minutes of cycling at an 
intensity of 60% heart rate reserve, participants experienced reductions in 24-hour ABPM of 3 
mmHg SBP and 2 mmHg DBP (Ciolac et al., 2008). A meta-analysis has reported reductions as 
high as 12 mmHg SBP in hypertensive individuals (Cardoso et al., 2010). Furthermore, more 
evidence is required in order to determine whether these reductions are observed in normotensive 
individuals following acute aerobic exercise (Cardoso et al., 2010). 
1.3.2 Chronic Effects of Aerobic Exercise on Blood Pressure 
 The BP lowering effects of chronic aerobic exercise have been well established (Cardoso 
et al., 2010). There is ample support for the efficacy of aerobic exercise intervention as an 
effective means of lowering resting BP (Pescatello et al., 2015). Despite differences in the 
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intensity of exercise (30-90% of maximum oxygen consumption), length of intervention (4-52 
weeks), duration of exercise 1-60 minutes, frequency (1-7 days/week) and exercise modality 
(walking, running, swimming, cycling), most types of aerobic exercise seem to produce 
reductions in BP (Pescatello et al., 2015; Cornelissen & Smart, 2013; Cornelissen & Fagard, 
2010; Kelley et al., 2001).  Manipulation of these exercise variables (i.e., higher intensity with 
greater frequency) can produce more pronounced reductions in BP. (Pescatello et al., 2015; 
Cornelissen & Smart, 2013; Cornelissen & Fagard, 2010; Kelley et al., 2001).  
 The exact mechanisms responsible for the BP lowering effects of chronic aerobic 
exercise remain inconclusive. Due to the complex nature of HTN etiology, the mechanism is 
likely a result of different interactive BP regulatory (i.e., neural, hormonal and local) pathways. 
Current evidence suggests that reductions in BP following chronic aerobic exercise are attributed 
to decreases in TPR, as opposed to changes in Q (Fagard, 2006; Cardoso et al., 2010). Moreover, 
this reduction in TPR is likely attributed in part to reductions in SNS activity, which attenuates 
vasoconstriction (Fagard, 2006). Furthermore, increases in circulating NO and decreases in ET-1 
induce greater dilation of blood vessels, resulting in lowered TPR and ultimately BP (McLean et 
al. 2015; Maeda et al., 2001). 
The effects of aerobic training on ABPM requires further investigation. Chronic aerobic 
training appears to produce reductions in 24-hour ABPM of approximately 8 mmHg SBP and 4 
mmHg DBP in normotensive, and 3 mmHg SBP and 4 mmHg DBP for hypertensive individuals, 
respectively (Cardoso et al., 2010). A recent meta-analysis examining the effects of >4 weeks of 
aerobic training has shown reductions in daytime ABPM of 3/3 mmHg in normotensives and 7/5 
mmHg in hypertensive individuals’ SBP and DBP, respectively (Cornelissen et al., 2013). 
However, aerobic training did not elicit any change in nighttime ABPM (Cornelissen et al., 
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2013). The mechanism(s) behind these reductions remain equivocal, but likely reflect the local 
and neurological pathways that are responsible for the reductions in resting BP.  
1.3.3 Acute Effects of Dynamic Resistance Exercise on Blood Pressure 
 An acute bout of dynamic resistance exercise, which involves utilizing muscular 
contractions of larger muscle groups to move a load placed upon that muscle (i.e., weight 
training), elicits an immediate and substantial increase in both SBP and DBP of upwards of 
>350/200 mmHg, respectively due to EPR (See Section 1.3.1; de Sousa et al., 2013; de Souza 
Nery et al., 2010; MacDougall et al., 1985). Individuals with HTN show greater elevations in 
SBP compared to normotensives when completing muscular contractions at matching intensities 
(de Souza Nery et al., 2010). These differences in BP response to dynamic resistance exercise are 
suggested to be the result of increased SNS activity at both rest and during exercise (de Souza 
Nery et al., 2010). Additionally, alterations in the RAAS system in hypertensive individuals may 
account for the greater BP attenuation (de Souza Nery et al., 2010). 
With respect to PEH, an acute bout of dynamic resistance exercise can elicit reductions in 
resting BP and 24-hour ABPM (Cassonatto et al., 2016). A recent meta-analysis found that a 
single bout of dynamic resistance exercise reduces resting SBP by 3 mmHg and DBP by 3 
mmHg at 1-hour post-exercise (Cassonatto et al., 2016). Greater reductions of 5/5 mmHg were 
observed at 90 minutes post-exercise for SBP and DBP, respectively (Cassonatto et al., 2016). 
Furthermore, a single bout of dynamic resistance exercise reduced 24-hour ABPM by 2/1 mmHg 
of SBP and DBP, respectively (Cassonatto et al., 2016). Notably, individuals with HTN observed 
greater reductions in resting BP (9 mmHg SBP and 5 mmHg DBP) compared to their 
normotensive counterparts (3 mmHg SBP and 3 mmHg DBP) (Cassonatto et al., 2016). Exercise 
intensity appears to influence PEH; resistance exercise completed at low intensity (40% of 1 
repetition max (1RM)) reduced SBP by 6 mmHg, while high intensity (80% 1RM) reduced SBP 
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by 8 mmHg (Rezk et al., 2006). Interestingly, only the low intensity exercise appeared to have an 
effect on DBP (Rezk et al., 2006). The higher intensity resistance training (80% 1RM) elicited 
augmentation in TPR compared to the lower intensity resistance training (40% 1 RM). This 
increase in TPR is suggested to be a counter regulatory mechanism to combat decreases in Q 
caused by losses in SV because of blood being forced from the vasculature into the intracellular 
space (Rezk et al., 2006). Also, the increase in HR and BP that occur during resistance exercise 
is directly proportional to the intensity of exercise (Rezk et al., 2006; Lamotte et al., 2005). 
Although evidence supporting resistance exercise-induced PEH remains inconsistent, these 
reductions are believed to be caused by muscle mass reperfusion and are equivalent to the size of 
the muscle recruited, as well as the volume and intensity of the exercise performed (Cassonatto 
et al., 2016; Rezk et al., 2006; Lamotte et al., 2005; MacDougal, 2002; MacDougal et al.,1985). 
1.3.4 Chronic Effects of Dynamic Resistance Exercise on Blood Pressure 
The body of literature supporting the regulation of BP by chronic exposure to resistance 
exercise is not nearly as extensive as that of aerobic exercise training. A recent meta-analysis 
examining the effects of 14 weeks of moderate intensity dynamic resistance training on BP has 
shown reductions in normotensives and hypertensives of approximately 3/2 mmHg and 6/5 
mmHg for SBP and DBP, respectively (MacDonald et al., 2016). Studies were matched for 
frequency (3 times per week), duration (14 weeks), intensity (60-70% 1RM) and training volume 
(3 sets, 11 repetitions) (MacDonald et al., 2016). As a result, the Canadian recommendations for 
hypertension management include dynamic resistance exercise as part of a comprehensive 
physical activity program to help reduce and maintain BP to within clinical target ranges 
(Nerenberg et al., 2018).  
Despite the reductions in ABPM following acute dynamic resistance exercise noted 
above, there is still no evidence to suggest that there are chronic BP reductions elicited from 
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dynamic resistance exercise (Cardoso et al., 2010). This lack of evidence is the result of an 
insufficient number of studies examining the effects of chronic dynamic resistance exercise on 
ABPM (Cardoso et al., 2010). Therefore, more data are needed before a sufficient conclusion can 
be drawn with regards to the chronic effects of dynamic resistance training on ABPM.  
1.4 Isometric Resistance Exercise (IRE) 
1.4.1 Acute Effects of Isometric Resistance Exercise on Blood Pressure 
IRE training is a novel BP-lowering exercise modality for the treatment of HTN. 
Typically, IRE protocols employ multiple, sustained muscular contractions at a set percentage of 
a maximum voluntary contraction (MVC), at which there are no changes to muscle length or 
joint angle (Millar et al., 2014). IRE has been recently endorsed by the American Heart 
Association and by Hypertension Canada as an alternative form of exercise for the treatment to 
decrease BP, particularly due to the ease of use and time-effective nature of this exercise 
modality (Whelton et al., 2017; Nerenberg et al., 2018; Carlson et al., 2014; Millar et al., 2014). 
The most common form of IRE is known as IHG training, which employs 4, 2-minute isometric 
contractions at an intensity of 30% of MVC value on a hand dynamometer, using alternate 
hands, conducted 3 times per week (Whelton et al., 2017). 
 The effects of IRE on PEH requires further investigation. In older normotensive 
individuals, reductions of 3 mmHg SBP have been observed immediately following 4, 2-minute 
IHG contractions at 30% MVC (Millar et al., 2009). In contrast, work by Ash and colleagues 
(2017) has shown that no PEH is observed in pre-hypertensives following the completion of 4, 2-
minute IHG contractions at 30% MVC (Ash et al., 2017). Similarly, work from Bartol and 
colleagues (2012) did not observe PEH following IHG training in well-medicated hypertensives 
(Bartol et al., 2012). This lack of observable PEH could be attributed to the BP modulating 
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effects of anti-hypertensive medication (Millar et al. 2009). Further investigation is needed to 
understand the acute cardiovascular responses following an acute bout of IHG. 
1.4.2 Chronic Effects of Isometric Resistance Exercise on Blood Pressure 
 The body of support for IRE training-induced reductions in BP is growing. Numerous 
studies have shown that IRE training can reduce resting BP in a variety of populations, using 
IHG and ILE training protocols (Inder et al., 2016; Carlson et al., 2014; Millar et al., 2014). In a 
recent meta-analysis, Inder and colleagues (2016) found reductions of 5 and 4 mmHg SBP and 
DBP, respectively, as well as a reduction in HR by 2 bpm following 8 weeks of IRE training in 
hypertensives and normotensives (Inder et al., 2016).  
 With respect to duration, participants who complete >8 weeks of IRE appear to have 
larger reductions in SBP (7 mmHg) compared to those who only completed <8 weeks of IRE (3 
mmHg); duration did not appear to influence DBP (Inder et al., 2016). As far as frequency is 
concerned, work from Badrov and colleagues (2013) investigated the IHG dose-response in 
normotensive women (n=32; age 18-45 years). Participants completed either 3 (n=11 IHG 
training sessions per week, 5 IHG training sessions per week (n=12) or 0 training sessions per 
week (n=9) (4, 2-minute sustained contractions at 30% MVC) for 8 weeks. Although both 
groups produced reductions in SBP of approximately 6 mmHg, the 5 times per week group 
elicited these reductions earlier at 4 weeks, rather than at the end of 8 weeks for the 3 times per 
week group (Badrov et al., 2013).   
 The body of research surrounding the effects of IHG training on ABPM is scarce. Work 
from Somani and colleagues (2017) found significant reductions in day time, night time and 24-
hour ABPM of 4 mmHg in young men and women with normal BP (Somani et al., 2017). Other 
work from Stiller-Moldovan and colleagues (2012) reported no significant change in medicated 
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hypertensives, although clinically relevant reductions were observed (Stiller-Moldovan et al., 
2015). The lack of significant findings was suggested to be the result of pharmacotherapy 
proficiently controlling BP (Stiller-Moldovan et al., 2012). Further evidence is required to 
determine whether IHG training can effectively reduce ABPM.   
 Despite the growing evidence supporting IHG reductions in resting BP, the exact 
mechanism(s) responsible for these reduction remains unknown. IHG-induced reductions in BP 
obtained through IRE are suggested to occur through complex interactions of numerous 
mechanism(s) encompassing modulations of ANS activity and improvement in endothelium 
dependent vasodilation (McGowan et al., 2017; McGowan et al., 2006; McGowan et al., 2007a; 
McGowan et al., 2007b; Taylor et al., 2003; Millar et al., 2009; Badrov et al., 2013). 
1.4.3 Surface Electromyography in Isometric Resistance Exercise  
 Surface EMG is a non-invasive technique used to measure the activity of muscle fibres. 
In brief, electrical activity of muscular contractions known as motor unit action potentials 
(MUAP) are tracked via electrodes placed on the surface of a muscle (Disselhorst-Klug et al., 
2009). EMG data are comprised of the summation of MUAP, are representative of the magnitude 
and frequency of which a muscle is recruited, and are used as an indirect measure of muscle 
force (Farfán et al., 2010; Deluca, 1997). However, EMG does not directly measure force 
exerted from a particular muscle, but rather measures the recruitment of muscle based on the 
pattern of MUAPs (Deluca, 1997). Therefore, force can only be estimated and is subject to error 
during interpretation (Farfán et al., 2010; Deluca, 1997). A linear relationship has been shown 
between EMG activity and muscular force, meaning that higher EMG activity is correlated with 
higher forces exerted by the muscle (Disselhorst-Klug et al., 2009).  
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During an isometric contraction, where the length of the muscle remains constant, EMG 
activity can be reflective of forces exerted by the exercising muscle, as there is no change in joint 
angle or muscle length that can alter the data (Disselhorst-Klug et al., 2009; Deluca, 1997). 
Fatigue can influence EMG activity. As a muscle maintains a sustained contraction at a 
particular force, the muscle begins to fatigue (Deluca, 1997). As a result, muscles are recruited 
more frequently and with larger amplitudes to maintain the necessary force desired (Deluca, 
1997; Solomonow et al., 1990).  
A potential limitation of surface EMG is the error in data collection due to the electrodes 
picking up electrical activity from surrounding muscles in a phenomenon known as “cross-talk”, 
which can potentially mask the activity of the examined muscle (Disselhorst-Klug et al., 2009). 
Another limitation to EMG is that biological tissues like skin, adipose, and muscle conduct 
electrical signals differently and differences in body composition can interfere with the EMG 
electrodes picking up MUAP signals (Deluca, 1997). Furthermore, improper recording of EMG 
data can occur if electrodes do not have proper contact with the skin due to excessive hair, or oils 
from the skin (Deluca, 1997). Finally, errors can exist within the analysis technique of the 
investigator (Farfán et al., 2010). Analysis techniques utilizing the root mean square (RMS) of 
the EMG data have been shown to be reliable for the interpretation of force and fatigue during 
both dynamic and isometric muscular contractions (Fukuda et al., 2010; Farfán et al., 2010) 
Despite these limitations, surface EMG has been shown to be a reliable tool for indirect 
determination of muscle exertion (Diesselhorst-Klug et al., 2009).  
Within the IRE literature, EMG is utilized as an alternative to MVCs as a determinant of 
exercise intensity (Deveraux et al., 2010; Wiles et al., 2010; Wiles et al., 2008). Participants 
perform maximum voluntary contractions, from which their peak EMG activity were obtained 
 34 
 
(Wiles et al., 2008). The exercise intensity was incrementally increased from 10-30 % peak 
EMG activity, during which HR and BP were recorded (Wiles et al., 2008). EMG activity was 
positively correlated with increases in both HR and SBP (Wiles et al., 2008).  Other work from 
Wiles and colleagues have utilized EMG to match exercise intensity to HR in order to produce 
increases in SBP and HR similar to those utilizing MVCs (Wiles et al., 2010). Alternatively, the 
literature surrounding EMG activity during a bout of IHG exercise is scarce. Some studies have 
examined the effects of EMG and BP in response to IHG exercise (Jacobsen et al., 1994; Cotzias 
& Marshall, 1993). It is interesting to note that higher EMG activity in the non-exercising limb 
during the IHG exercise was found to be associated with decreased TPR during the contraction 
(Jacobsen et al., 1994; Cotzias & Marshall, 1993). Despite these reductions in TPR elicited from 
IHG, the relationship between EMG in the exercising arm and BP in response to IHG exercise, 
remains to be quantified. 
1.4.4 Feasibility of Isometric Resistance Exercise Devices 
 As noted above, isometric exercise has been shown to be an effective modulator of 
resting BP. Although IRE training has been shown to elicit reductions in BP, protocols have 
primarily been contained to a laboratory setting due to the equipment used (see below for 
details). Although recent evidence (Goldring et al., 2014; Wiles et al., 2016) suggests that home-
based IRE training may be feasible, due to the portable nature of IHG devices and the use of 
hands versus legs (minimizes influence of lower body mobility and/or joint-related issues), IHG 
training may be a more favorable exercise modality. Unfortunately, 85% of Canadians are not 
meeting daily recommended exercise requirements, and with a growing number of Canadians 
who are unable to control their BP, novel exercise strategies must be explored (Statistics Canada, 
2014a; Statistics Canada, 2014b). Therefore, the implementation of IHG training may be one 
such novel intervention that can be easily implemented into daily living and may promote better 
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exercise adherence. Currently, the computerized dynamometers utilized in many IHG training 
studies to date cost upwards of $500 CAD (Zona Health, 2018). The cost associated with 
purchasing IHG equipment potentially establishes an economic barrier for those with HTN who 
cannot afford this alternative exercise modality.  
Currently, studies examining the effects of cost-effective alternatives to traditional IRE 
devices are limited and involve small numbers of primarily normotensive participants. Garg and 
colleagues (2014) examined the effects of 10 weeks of IHG training on resting BP in young 
normotensives utilizing a spring-loaded handgrip (Garg et al., 2014). Participants completed 5, 3-
minute sustained contractions at 30% MVC, 3 times a week for 10 weeks (Garg et al., 2014). 
Upon completion of the 10 weeks of training, resting BP was reduced 10 mmHg and 6 mmHg 
SBP and DBP, respectively (Garg et al., 2014). This is consistent with the findings from Millar 
and colleagues (2008) who examined the effects of IHG training performed 3 times a week for 8 
weeks utilizing an inexpensive spring-loaded handgrip device in older normotensive individuals 
(Millar et al., 2008). Participants were paired with a spring-loaded handgrip device with a low, 
medium or high resistance, respectively, which corresponded to approximately 30-40% MVC 
calculated utilizing a computerized hand dynamometer (Millar et al., 2008). Following 8 weeks 
of IHG training, significant reductions in resting BP of 10 and 3 mmHg SBP and DBP, 
respectively were obtained (Millar et al., 2008). These findings suggest that similar reductions in 
resting BP can be achieved utilizing less expensive alternative IHG devices. However, the 
handgrips had to be outfitted with implanted pressure gauges by the research investigators, and 
thus remain problematic for large‐scale prescription. Furthermore, little is understood about the 
acute cardiovascular or neuromuscular responses of these IHG alternative devices and no study 
to date has directly compared devices.     
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 In addition, EMG equipment is expensive and requires training for proper use, making it 
an unfeasible exercise modality for the average person (Wiles et al., 2016). This gap in easily 
available home IRE exercise sparked a study by Goldring and colleagues in 2014 that attempted 
to quantify a stimulus using a static wall sit exercise, similar to traditional IRE training, that 
could elicit reductions in BP (Goldring et al., 2014). Normotensive participants completed 2 
minutes of isometric wall squats with knee angles from 135 to 90 degrees in 5-degree intervals, 
with BP and HR measured at rest and continuously throughout the 2-minute contractions 
(Goldring et al., 2014). An inverse relationship was discovered between knee angle and BP and 
HR (Goldring et al., 2014). This allows for incremental determination of exercise intensity that 
can match traditional IRE literature utilizing an intensity of 95% peak HR (Goldring et al., 2014; 
Deveraux et al., 2010; Wiles et al., 2010). A study conducted by Wiles and colleagues (2016), 
also with young, healthy normotensives, examined the effects of utilizing isometric wall sits on 
resting BP in a training study (Wiles et al., 2016). Participants completed 4, sustained 2-minute 
sits at a participant-specific knee joint angle that corresponded to 95% peak HR, 3 times a week 
for 4 weeks (Wiles et al., 2016). Following 4 weeks, resting BP was reduced by 4 and 3 mmHg 
SBP and DBP, respectively, as well as reduced resting HR by 5 beats per minute (Wiles et al., 
2016).  
These results support the use of IRE as an effective means to lower resting BP that can be 
completed without the use of expensive equipment in the comfort of one’s own home. Further 
research is required to support the real-world implementation of IRE and help to reveal the 
potential mechanism(s) of action regarding how IRE lowers resting BP. 
1.4.5 Gaps in the Existing Isometric Resistance Exercise Literature 
The body of support for IRE training as a means of lowering resting and ambulatory BP 
is continually growing. Despite the recent endorsements from the AHA and Hypertension 
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Canada, IRE has yet to be as widely accepted as traditional aerobic and dynamic resistance 
exercise as an effective exercise modality (Whelton et al., 2017; Nerenberg et al., 2018). As 
noted in Section 1.4.3 above, cost-effective alternatives appear to induce similar reductions in 
resting BP as traditional IRE equipment (Wiles et al., 2016; Garg et al., 2014; Goldring et al., 
2010; Miller et al., 2008). Despite these similarities, the feasibility of matching the exercise 
intensity between devices, and quantifying the acute effects of IHG exercise utilizing 
inexpensive IHG devices, remains to be explored.  
Because the exact mechanism(s) of how IRE-reduced BP have yet to be fully determined, 
it is still valid to examine responses to different exercise stimuli. Currently, evidence directly 
examining the differences in BP, HR, or muscular activation between traditional IRE devices and 
cost-effective alternatives, is limited. The findings from Goldring et al. (2010) and Wiles et al. 
(2016) indicate that quantifying the exercise stimulus allows for matching of exercise intensity 
without the need for expensive equipment that can elicit reductions in resting BP and HR 
(Goldring et al., 2010; Wiles et al., 2016).  
During sustained muscular contractions, subjective ratings of perceived exertion (RPE) 
have been correlated with muscular activation (via EMG) and have been shown to be predictive 
of fatigue (Troianoa et al., 2008). However, little is known of the perceived effort and discomfort 
associated with IRE exercise itself and how effort, pain or fatigue may affect implementation of 
IRE as a mainstream exercise tool. Work from Wiles and colleagues (2005) examined the BP, 
HR and RPE between three IRE devices; one IL device utilizing a force transducer, two utilizing 
an arm contraction at the elbow (one utilizing a novel device and one utilizing a force transducer) 
(Wiles et al., 2005). Participants completed 4, 2-minute sustained contractions on each device 
while SBP, DBP, HR and RPE were collected throughout (Wiles et al., 2005). Significant 
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differences were found only in SBP between the two upper limb devices with the transducer 
device eliciting an elevation of 9 mmHg greater than the novel device (Wiles et al., 2005). No 
significant differences were found for DBP, HR or RPE between the three devices (Wiles et al., 
2005). Integration of both subjective and objective measures of physiological response to IRE 
may provide insight into not only the effectiveness of inexpensive IRE equipment, but also the 
feasibility of implementing less expensive IRE devices to lower BP. 
 Despite the effectiveness of IHG exercise at reducing BP, it has only recently made it into 
international guidelines (Whelton et al., 2017; Nerenberg et al., 2018). Furthermore, more 
evidence is required into cost-effective alternatives. Furthermore, the acute IHG stimulus for 
these inexpensive alternatives remains to be investigated. Moreover, whether alternative devices 
are comparable in terms of subjective ratings of exertion may provide insight into how adherence 
to exercise training interventions would be for these handgrips. Additionally, understanding the 
acute stimulus may provide insight into the potential mechanism(s) responsible for IHG-induced 
BP reductions.  
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2.1 Introduction 
Hypertension (HTN), or high blood pressure (BP), is an increasing public health concern. 
Affecting nearly 5.3 million Canadians (Statistics Canada, 2013), hypertension increases an 
individual’s chances of developing cardiovascular diseases (CVD), such as a heart attack or 
stroke (Public Health Agency of Canada, 2009). Identified recently as a global health crisis by 
the World Health Organization (WHO), hypertension is defined as a chronic elevation in resting 
BP of >130/80 mmHg or 135/85 mmHg using automated office BP (AOBP) measurements 
(Nerenberg et al., 2018; Whelton et al., 2017). Lifestyle modifications such as cessation of 
smoking, limiting alcohol consumption, proper nutrition and participation in regular exercise are 
cornerstone treatments for BP management (Nerenberg et al., 2018; Whelton et al., 2017; 
Blumenthal et al., 2010). In many cases, pharmacotherapy is prescribed in addition to traditional 
lifestyle modifications to reach target BP values (Nerenberg et al., 2018). Upwards of 50% of 
people treated for hypertension in Canada are not controlled to target levels (Nerenberg et al., 
2018). Failure to achieve target BP greatly increases the risk of HTN-related complications such 
as a heart attack or stroke (Sarafidis, 2011). Thus, the implementation of new treatments that 
effectively lower, and then maintain BP, is essential.   
Isometric handgrip (IHG) training is one such novel intervention which has been put 
forth by international organizations as an effective intervention to achieve BP control (Nerenberg 
et al., 2018; Whelton et al., 2017). IHG training, which employs 4, 2-minute sustained 
contractions at an intensity of 30% of maximum voluntary contraction (MVC) on a hand 
dynamometer, using alternate hands, is conducted 3 times per week (Whelton et al., 2017). 
Numerous studies have shown that this simple and time-efficient form of exercise 
training can lower BP (i.e., mean reductions between 3 to 6 mmHg systolic BP and 4-6 mmHg 
diastolic BP) across a wide array of populations ranging from young normotensive individuals to 
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older individuals with diagnosed hypertension (McGowan et al. 2017; Inder et al., 2016; Carlson 
et al., 2014; Miller et al., 2014).  
A current barrier to the implementation of IHG training as a mainstream intervention tool 
for those with hypertension, and thus the widespread endorsement of the American Heart 
Association/Canadian Hypertension guidelines in clinical practice and community-based 
exercise programs, is the high cost associated with the traditional computerized IHG 
dynamometers. Currently, the price for these traditional computerized devices cost upwards of 
$500 (CAD) (Zona Health, 2018). Although there is some research to suggest that less expensive 
spring-loaded devices offer similar benefits to more costly alternatives, the exercise in this work 
was limited to a laboratory setting (Garg et al., 2014; Millar et al., 2008). More specifically, the 
devices required research investigators to outfit the handgrips with pressure gauges to calculate 
appropriate exercise intensity, and thus remain problematic for large-scale prescription within the 
community (Garg et al., 2014; Millar et al., 2008). Thus, research into the effectiveness of 
alternative, commercially available, inexpensive handgrips is necessary.  
As a preliminary step before implementing training studies utilizing cost-effective IHG 
devices, the IHG stimulus must be quantified in attempt to best match the response from 
existing, and effective, computerized IHG device. By better understanding what happens to the 
cardiovascular and neuromuscular systems during an acute bout of IHG utilizing the traditional 
and less costly IHG devices, a better understanding of the associated BP-lowering mechanism(s) 
may result.  No study to date has attempted to compare the IHG stimulus across devices. 
Moreover, other IRE studies have used surface electromyography (EMG) in order to determine 
exercise intensity by measuring muscular activation (Wiles et al., 2010). Therefore, by muscle 
recruitment via surface EMG that occurs as a result of using the traditional computerized 
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dynamometer, to that from an inexpensive mechanical handgrip device, may allow for a more 
accurate comparison of devices. Additionally, there is little known about how a bout of IHG is 
perceived by the participant (e.g., how much effort is involved in performing the exercise and/or 
any associated discomfort). Integrating psychophysiological measures such as ratings of 
perceived exertion (RPE) and subjective discomfort through a numerical pain rating scale for 
pain (NRS Pain) will help determine whether alternative devices are comparable to traditional 
devices in terms of perceived effort and discomfort. Furthermore, developing a better 
understanding of the psychophysical factors associated with IHG training may provide insight 
into the potential adherence of IHG as a mainstream exercise tool to lower BP. 
2.2 Research Questions 
 Research Question 1: Will an acute bout of IHG utilizing an inexpensive mechanical 
handgrip device elicit a similar cardiovascular response (HR and BP) as the traditional 
computerized dynamometer? 
 Research Question 2: Will an acute bout of IHG utilizing an inexpensive mechanical 
handgrip device elicit similar muscular activation as the traditional computerized dynamometer? 
 Research Question 3: Will an acute bout of IHG utilizing an inexpensive mechanical 
handgrip device elicit similar subjective ratings of perceived exertion (RPE) and pain on a 
numeric rating scale (NRS Pain) during IHG exercise? 
2.3 General Methodology  
2.3.1 Study Participants   
Thirty-one young (age=18-30 years), healthy [no overt disease, not taking prescription 
medication with the exception of birth control pills (women were tested in the early follicular 
phase of the menstrual cycle if not on hormonal contraceptives, or during the low hormone phase 
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if on contraception) and free of physical limitations to use the devices] participants were 
recruited from the University of Windsor population and surrounding area. This included 
undergraduate and graduate students, faculty and staff, and community members. With an 
assigned alpha of 0.05, and a beta of 0.8, sample sizes ranging from 36 to 40 were estimated to 
effectively examine the electrical activity of the muscles of the upper extremity, cardiovascular 
responses, and subjective ratings to a single bout of IHG (Faul et al., 2007). Potential participants 
were recruited via poster campaign, presentations to research laboratories, undergraduate classes 
and/or community exercise facilities (e.g., gyms, community centres), word of mouth, and/or via 
email (See Appendix A for recruitment materials). Participants were excluded from engaging in 
the study if resting AOBP exceeded 135 and/or 85 mmHg SBP and DBP, respectively. 
Participants were also excluded if there was the presence of overt disease; if they were taking 
prescription medication (except for contraceptive medication); if there was the presence of 
physical limitations that impeded the use of the training devices; and/or if the participant 
indicated an allergy to any of the materials used for attaching the EMG instrumentation to their 
skin (e.g., electrode adhesive, adhesive on tape). 
2.3.2 Study Design  
Overview:  
Eligible participants performed a bout of IHG on a computerized IHG dynamometer 
(IBX H‐101, Zona Health, Boise, ID, USA; See Appendix B) and an inexpensive, store-bought 
mechanical grip (239247305, www.dhgate.com; See Appendix C) during a single testing session. 
A 30-minute stabilization period separated each bout. During each bout, beat-to-beat HR, 
minute-to-minute BP, ratings of perceived exertion, pain ratings and unilateral EMG data of the 
upper extremity were obtained. The total time to complete the collection procedures was 
approximately 4 hours, which included 3 points of contact, as described below.  
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Eligibility and Familiarization Session:  
Visit 1 (Figure 1. A) 
First, the primary investigator thoroughly explained the study, and asked potential 
participants to read a consent form and information sheet related to the study (See Appendix D 
and E). Those still interested in taking part in the study signed a consent form and were given a 
copy of the information sheet for their personal records.   
The participants who provided consent completed a medical questionnaire and a Physical 
Activity Readiness Questionnaire (See Appendix F), with the intent of screening for the presence 
of any condition that would exclude them from the study. As the last step to determine eligibility, 
potential participants had their resting AOBP measured in their dominant arm to ensure they met 
the inclusion criteria (<135/85 mmHg). Resting AOBP was measured per standard laboratory 
protocol. In brief, resting AOBP was measured following 10-minutes of seated rest using 
brachial artery oscillometry (Dinamap Carescape v100, Critikon, Tampa, Florida, USA; See 
Appendix G). AOBP was measured by placing a cuff on the upper portion of the participant’s 
dominant arm, and the cuff was automatically inflated to a pressure greater than the systolic BP 
to occlude the brachial artery. Four measurements were acquired, with 2-minute rest periods 
between each measurement, and the last 3 BP values were averaged. Using the BP data, together 
with the medical questionnaire, final eligibility of the potential participant was determined. At 
this time, participants were encouraged to ask any remaining questions, and were reminded of 
their right to withdraw from the study at any time. Eligible participants were then scheduled for a 
familiarization session, where they had an opportunity to practice all portions of the 
investigation.   
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Familiarization Session 
Visit 2 (Figure 1.B) 
At least 24 hours after the initial visit, a familiarization session occurred. Interested 
participants who met the inclusion criteria, were still interested in engaging in the study, and who 
refrained from vigorous physical activity over the previous 24 hours, were tested 2 hours post-
prandial and at least 12 hours post-caffeine. To minimize the effects of a full bladder on BP as 
having a full bladder can raise BP, participants were asked to void prior to the familiarization 
session.  
Participants provided on-going consent by initialling the visit 2 consent section of the 
consent form. They were then given 10 minutes of seated rest after which 4 resting BP values 
were taken as noted above. Following those measures, they were outfitted with the necessary 
equipment to gather EMG data. More specifically, two electrodes were attached to the largest 
part of each muscle, parallel to the primary fascicle direction of the following muscles: flexor 
carpi ulnaris (FCU), brachioradialis (BR), extensor carpi ulnaris (ECU), brevis/longus, biceps 
brachii (BB) and triceps brachii (TB) with the arm held at a 90 degree angle at the elbow. The 
placement for the electrodes were as follows: BB: 1/3 of the distance proximally from the cubital 
fossa between the acromion and cubital fossa. BR: 2 finger breadths from the cubital crease with 
forearm in neutral position. TB: 2 finger breadths medially at 50% of distance between the 
acromion and the olecranon. ECU: 1/3 of the distance from the lateral epicondyle between the 
lateral epicondyle and the ulnar styloid. FCU: 2 fingerbreadths from the ulnar border on the 
proximal third of the forearm (Zip, 1982) (Figure 2).  The skin to which the electrodes were 
attached was shaved with a disposable safety razor (if needed) and then cleaned with an alcohol 
swab prior to attaching the electrodes (PUN-96, Bortec Biological Limited, Calgary, Alberta, 
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Canada; See Appendix H).  A low allergy surgical tape was placed over the electrodes and 
adhered to the skin to provide additional adherence and limit any electrode movement during 
data collection.  
Participants were then randomly assigned to either a computerized IHG dynamometer 
(IBX H‐101, Zona Health, Boise, ID, USA); Appendix B) or an inexpensive store-bought 
mechanical grip (> $10) (239247305, www.dhgate.com; Appendix C). They were then asked to 
perform 3 maximal 2-second squeezes separated by 1-minute of rest between squeezes. 
Following the third squeeze, participants completed one 2-minute sustained contraction at an 
intensity of 30% of their maximum squeeze, during which BP and HR measurements were taken 
each minute. Following the completion of each 2-minute contraction, the participant was asked 
to rate their perceived exertion using the Borg 6-20 rating of perceived exertion scale (Appendix 
I; Borg, 1998) and to rank any discomfort that they may have experienced on a 1-10 numeric 
pain scale (Appendix J; Borg, 1998).  After a 10-minute rest period, participants completed the 
same protocol utilizing the other handgrip device. Once the aforementioned protocol was 
completed, and if the participant was still interested in engaging in the study, visit 3 was 
scheduled at least 24 hours later.  
Testing Day  
Visit 3 (Figure 1C) 
  At least 24 hours after visit 2, a single testing session occurred. All participants were 
tested in the morning in a temperature-controlled room (PACR Laboratory). Participants were 
asked to have refrained from vigorous physical activity over the previous 24 hours, were tested 2 
hours post-prandial and at least 12 hours post-caffeine. To minimize the effects of a full bladder 
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on BP, participants were asked to void prior to testing. Participants were asked to provide on-
going consent by initialling the visit 3 section of the consent form. 
Participants were seated for the duration of the testing period, with both their right and 
left forearms resting on a table in front of them with their elbows at approximately 90 degrees. 
First, participants were outfitted with the necessary equipment to acquire BP and HR (See 
Appendix G), and EMG (See Appendix H). Resting AOBP was measured following 10 minutes 
of seated rest, as described above. Next, participants performed (in random order) an IHG 
protocol on the traditional, computerized IHG dynamometer and the mechanical grip. The 
protocols were separated by at least 30-minutes of rest or until the participant’s BP returned to 
near pre-exercise values. In both conditions, the IHG bout consisted of 4, 2-minute unilateral 
(non-dominant arm) contractions at 30% of their MVC, each separated by a 4-minute rest period. 
The procedure for determining exercise intensity was as follows: 1) For the computerized 
dynamometer, MVC was determined at the onset of the protocol in the non-dominant hand using 
linear load cells inherent to the device, whereby 30% MVC was automatically calculated by the 
device using these data, 2) For the mechanical handgrip, the MVC was determined by having the 
participant maximally squeeze the handgrip, again with their non-dominant hand, against the 
resistance of the handgrip which was quantified by turning a dial on the device. Therefore, 30% 
MVC was manually calculated based on the maximum load determined from the dial. Upon 
completion of each 2-minute contraction, the participant was asked to rate their perceived 
exertion using the Borg 6-20 rating of perceived exertion scale (RPE) (See Appendix I; Borg, 
1998), and to rank any discomfort that they may have experienced on a 1-10 numeric rating scale 
for pain (NRS Pain) (See Appendix J; Hawker et al., 2011). 
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All data were collected continuously for 10 minutes prior to, during, and for at least 30 
minutes following each IHG bout. Specifically, AOBP was measured each minute in the 
dominant (non-exercising) limb using the device described above. During each bout of the 4, 2-
minute contractions, the peak value of SBP, DBP and HR for both the mechanical and 
computerized IHG devices were obtained every minute utilizing automated oscillometry. Next, 
pre-exercise values (blood pressure reading taken just before the onset of the exercise) were 
subtracted from peak exercise values for each of these three variables in order to create a delta 
score for each variable. These delta scores were then compared between the two devices to 
determine the peak acute stimulus for SBP, DBP and HR.  On the non-dominant (exercising) 
limb, EMG data were obtained using the same protocol described above. During each 2-minute 
contraction, raw surface EMG data were collected at a sampling rate of 2k/s. Raw EMG data 
were rectified, filtered using a low pass Butterworth filter with a cut-off frequency of 2 Hz, and 
normalized to the peak activity of 2-second MVC trials. All data was normalized to each 
participant peak surface EMG score from the 2-second contraction for each muscle. Normalized 
EMG was averaged over time intervals (2 sec) representing 5 epochs during each contraction. 
Participants were encouraged to keep their arm flexed at a 90-degree angle throughout the 2-
minute contractions to prevent changes in joint angle and muscle length from influencing the 
EMG data. Surface EMG data were subdivided into 5, 2-second time epochs within 22 second 
time intervals spanning 110 seconds (first 10 seconds of each contraction was excluded to 
accommodate the participant acclimating to 30% MVC resistance) (Figure 3). Upon completion 
of each 2-minute contraction, participants were asked to rate their RPE (See Appendix J) and 
NRS-Pain (See Appendix K) during the isometric exercise.  
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(A) 
 
  Inclusion and exclusion criteria 
-Reviewed and signed consent form 
-Receive letter of information 
-Medical questionnaire and PAR-Q 
-10 min. seated rest 
-Resting BP and HR measured (4X, 2 min. rests between 
measurements) 
**Resting BP < 135/85mmHg: 
schedule visit 2 
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(B) 
       
 
 
 
 
  
10 min. seated 
rest 
Random assignment of 3, 2-sec. MVC 
with 1-min rest intervals in between. 
Followed by 1, 2-minute unilateral IHG 
contraction at 30% of the last MVC 
• No alcohol for 24 hours 
• No vigorous exercise for 24 hours 
• No caffeine for 12 hours 
• 2 hours post-prandial 
• Refrain from lotion 
• Empty bladder 
• Isolated, quiet, temperature-controlled room 
4 resting BP/HR measurements, 2 min. rest 
intervals in between 
10 min. stabilization between trials 
Familiarization Day (~ 1 hr.)  
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(C)  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Study design: (A) Visit 1: initial visit: determination of eligibility is conducted (B) Visit 
2: familiarization session where participants experience all testing procedures and protocol prior 
to testing (C) Visit 3: testing day  
10 min. seated 
rest 
Random assignment of 3, 2-sec. MVC 
with 1-min rest intervals in between. 
Followed by 1, 2-minute unilateral IHG 
contraction at 30% of the last MVC 
(A) No alcohol for 24 hours 
(B) No vigorous exercise for 24 hours 
(C) No caffeine for 12 hours 
(D) 2 hours post-prandial 
(E) Refrain from lotion 
(F) Empty bladder 
(G) Isolated, quiet, temperature-controlled room 
10 min. stabilization between trials 
Testing Day (~ 2.5 hr.)  
Random assignment of 4, 2-min unilateral IHG 
contractions at 30% MVC with 4 min. rest intervals 
in between. 30 minute stabilization between trials 
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Figure 2: EMG Electrode Placement of electrodes on the non-dominant arm. 
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Figure 3: EMG data analysis protocol for extracting surface EMG data and binning of the data 
for analysis. Raw EMG was collected at a sampling rate of 2k/s (A). Data was rectified and a 
Butterworth filter with a cut-off frequency of 2 Hz was added to provide a linear envelope (B). 
Linear envelope data corresponding to 2- second MVC trials and 2-minute contractions were 
used from each muscle for analysis. Peak EMG scores for each muscle during the MVC trial 
were used to normalize data. The first 10 seconds of each 2-minute contraction was excluded to 
allow for acclimatization to the 30% MVC exercise intensity. The remaining 110 seconds were 
subdivided into 5, equal 22-second intervals. A 2-second epoch was taken from the middle of 
each of the 5 time intervals and used for analysis (C). 
A
. 
B
. 
C
. 
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2.3.3 Statistical Analysis  
 To examine the acute exercise effects of the independent variable of IHG device type 
(computerized and mechanical) on the dependent variable of peak change in arterial BP (SBP 
and DBP) and HR across the 4 isometric contractions, a 2 x 4 repeated measures ANOVAs was 
conducted. Furthermore, the dependent variable of muscular activation (i.e., EMG) of the 
exercising arm for the BR, FCU, ECU, BB and TB muscles was analysed using a 2 x 4 (IHG 
type x contraction repeated measures ANOVA. Finally, both subjective measures of exertion 
(RPE and NRS Pain) with the device type as independent variable and peak rating score as 
dependent variable were analyzed utilizing a 2 x 4 (device type x peak rating score per 
contraction) repeated measures ANOVA. Sex (male or female), and order (starting handgrip) 
were analyzed as confounding variables to rule out the potential of these factors influencing the 
dependent variables. All data were analyzed using IBM SPSS Statistics 21 software (SPSS Inc., 
Chicago, Illinois, USA), data are presented as means and SD unless otherwise noted, and 
statistical significance was determined at p < 0.05. 
2.4 Results 
 Of the 33 participants recruited, 5 were excluded based on not meeting the eligibility 
criteria (i.e. resting BP above 135/85 mmHg, the presence of a diagnosed medical condition or 
taking prescription medication other than birth control medication). Additionally, at visit 1, 2 
eligible participants withdrew from the study for personal reasons. Furthermore, 6 participants 
withdrew from the study following visit 2 and did not complete visit 3, and therefore were 
excluded from data analyses. Twenty participants completed all three visits of the study and were 
included for analysis. Mean participant characteristics are outlined in Table 1.   
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Table 1: Participant characteristics 
Characteristics  
N 20 
  
Women 9 
Age (years)      22.4 ± 2.2 
Mass (kg)  77.8 ± 27.0 
Height (cm)  163.4 ± 18.3 
Resting SBP (mmHg)  113 ± 11 
Resting DBP (mmHg) 63 ± 6 
Resting MAP (mmHg) 80 ± 7 
Resting HR (bpm)     70 ± 8 
SBP, systolic blood pressure; DBP, diastolic blood pressure; MAP, mean arterial pressure; HR, 
heart rate. Values are mean ± SD.  
2.4.1 Comparison of Acute Effects of Isometric Handgrip Exercise on Blood Pressure and Heart 
Rate Between Handgrip Devices  
 No statistical differences were observed for peak SBP (p = 0.11) and HR (p = 0.18) 
between devices (Table 2). Moreover, a statistically significant interaction was found between 
device type and sex for SBP (p = 0.05). A Tukey’s post hoc test revealed that a statistically 
significant elevation in SBP for male participants using the mechanical handgrip (15 ± 11 
mmHg) compared to the computerized device (7 ± 14 mmHg) (p = 0.00). A statistically 
significant increase was observed in DBP (p = 0.03) using the computerized device mmHg 
compared to the mechanical handgrip. Additionally, a significant interaction was found for 
device type and sex for DBP (p = 0.02). A Tukey’s post hoc analysis revealed that when using 
the mechanical device, male participants had higher DBP elevations than did their female 
counterparts. Furthermore, no significant difference was found for potential confounding 
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variables of contraction or device starting order (all p>0.05). However, due to the low observed 
power across measures, these results should be interpreted with caution. 
Table 2: Acute cardiovascular effects of isometric handgrip exercise utilizing the mechanical 
and computerized devices 
Change from Pre-Exercise 
to Peak Exercise Values 
Mechanical 
Handgrip Device 
Computerized 
Handgrip Device 
Observed Power 
    
SBP (mmHg) 12 ± 13 8 ± 10 0.35 
DBP (mmHg) 5 ± 13 6 ± 10 * 0.63 
HR (bpm) 1 ± 9 9 ± 8 0.26 
SBP, systolic blood pressure; DBP, diastolic blood pressure; HR, heart rate. Values are mean ± 
SD. *Significant difference between handgrip devices for DBP p <0.05.  
2.4.2 Comparison of Acute Effects of Isometric Handgrip Exercise on Muscular Activation 
Between Handgrip Devices  
 A statistically significant interaction was observed for the BB (p = 0.03) and BR (p = 
0.03) for device and contraction. However, for the purposes of this study these were deemed 
non-meaningful relationships and therefore main effects were examined. for all the muscles. No 
statistically significant interactions were found between the two devices for the BR, FCU or TB 
muscles (all p > 0.05). However, statistically greater elevations in muscle activation were 
observed when using the mechanical versus computerized device for BB (p = 0.02) and ECU 
(p=0.00) (Table 3). Due to the low observed power, these findings should be interpreted with 
caution. 
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Table 3: Acute muscle activations (%MVC) of isometric handgrip exercise utilizing the 
mechanical and computerized devices 
Change from %MVC 
 
Mechanical 
Handgrip Device 
Computerized 
Handgrip Device 
Observed Power 
    
BR 321.5 ± 322.9 304.7 ± 318.7 0.46 
ECU 
 
183.6* ± 130.0 173.6 ± 124.5 0.83 
FCU 
 
BB 
 
TB 
 
432.9 ± 905.3 
175.6* ± 247.3 
254.8 ± 201.5 
402.1 ± 822.6 
163.8 ± 235.1 
238.1 ± 204.6 
0.25 
0.67 
0.13 
BR, brachioradialis; FCU, flexor carpi ulnaris; ECU, extensor carpi ulnaris; BB, biceps brachii 
and TB, triceps brachii Values are mean ± SD. *Significant difference BB and ECU (p<0.05).  
2.4.3 Comparison of Acute Effects of Isometric Handgrip Exercise on Subjective Ratings of 
Perceived Exertion and Pain Between Handgrip Devices  
 No statistically significant differences were observed in either RPE (p = 0.12) or NRS-
Pain scores (p = 0.57) between devices (Table 4). A statistically significant main effect for 
contraction on RPE scores was observed (p = 0.00). A Tukey’s post hoc test revealed that with 
both devices, contractions 3 and 4 yielded elevations in RPE scores as compared to contraction 
1. However, a statistically significant interaction was found for sex and contraction (p =0.01) for 
RPE. Furthermore, no statistically significant differences were found for the potentially 
confounding variables of device starting order for both RPE and NRS-Pain scores. Interestingly, 
when participants were asked to state which handgrip was their preferred device, all 20 
participants stated that they preferred the computerized handgrip.  
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Figure 4: The acute effects of IHG on subjective ratings of RPE between contractions for both 
handgrip devices (p<0.05) Error bars ± SE. * significant differences for RPE between 
contractions (p <0.05). 
 
2.5 Discussion 
 This study is the first to directly compare the IHG stimulus response when performed 
using a traditional computerized dynamometer and an inexpensive mechanical alternative. No 
study to date has examined the acute BP and HR response between traditional computerized 
handgrips and less expensive handgrip devices. Furthermore, the incorporation of surface EMG 
may allow for a more accurate understanding of muscular activation levels during the exercise 
which helps more comprehensively quantify the IHG stimulus. Lastly, incorporating subjective 
measures of pain and perceived exertion may provide evidence for the pragmatic implementation 
of cost-effective alternative devices for IHG exercise.  
 
  
* 
* * 
 81 
 
Acute Cardiovascular Effects During IHG Exercise 
 Currently, little is known about what happens to BP and HR during IHG exercise. 
Evidence has examined the acute cardiovascular effects regarding post-exercise hypotension 
(Ohler et al., 2013). Additionally, there is some work in hypertensive individuals examining peak 
cardiovascular changes (Olher et al., 2013). This study provides insight into the acute BP and HR 
response during the IHG exercise in a young, normotensive population using different IHG 
devices. As stated above, no statistically significant differences were observed in terms of SBP 
or HR between the two handgrip devices. In contrast, significant DBP differences were found, 
with the computerized device eliciting a greater response than the mechanical device.  
Acute Effects on Muscular Activation During IHG Exercise 
 Through surface EMG, the present study examined the extent of muscular activation in 
the upper extremity during the IHG exercise. Muscular activation was similar for 3 of the 5 
muscles tested during contractions using the mechanical handgrip device. The one muscle that 
was significant was the ECU. The reason for this muscle being activated more could be due to 
differences inherent to the mechanical handgrip device itself. The two devices differed in design 
which could have resulted in more activation of the ECU compared to the computerized device.  
There is evidence to suggest that joint angle may influence EMG readings (Rabbi et al., 
2017; Duque et al., 1995). As muscles change in length as a result to movement of joint angle, 
both force production and EMG values may be affected (Rabbi et al., 2017; Duque et al., 1995). 
Participants were instructed to keep their arm at a 90-degree angle, however, without the limb 
being mechanically fixed in that position, slight perturbations in the wrist or arm posture could 
have led to changes in EMG values. Moreover, the MVC trial was completed in the same fixed 
posture as the participants were in during testing. By doing this, the muscles may not have been 
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able to contract with their maximal effort. Therefore, MVC scores were not representative of the 
full activation of each muscle but perhaps just a peak EMG score during the maximal forces 
obtained whilst in that determined posture. This is apparent in the values being numerous times 
greater than 100% MVC. Despite this limitation, both trials on each device utilized the same 
fixed posture and 30% of the force during the maximum voluntary contraction was used to 
determine exercise intensity, and not 30% of the peak EMG activation. Therefore, the EMG 
values represent the percentage of peak muscle activation during the exercise relative to the 
original activation in the fixed 90-degree posture during the MVC trial and not the absolute peak 
EMG activation of the muscle itself. 
Acute Effects on Perceived Subjective Pain and Exertion  
 To date, no IHG study has simultaneously investigated pain and ratings of perceived 
exertion during an exercise bout. Previous literature has shown that high intensity and/or painful 
past physical activity can act as a deterrent for future exercise (Lee et al., 2016).  
 The findings suggest that the mechanical handgrip device is no more painful and required 
a similar level of exertion compared to the computerized device. This may be the result of 
fatigue setting in as this trend still held true despite randomization of device order. Moreover, 
upon completing the final 30-minute rest period, all participants were asked to state which 
handgrip device they preferred. All 20 participants reported that they preferred the computerized 
handgrip device. This subjective finding suggests that the mechanical device may not be an ideal 
device to implement as an alternative IHG training device. 
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Limitations 
Although the findings provide compelling evidence of the mechanical handgrip being a 
comparable stimulus to the computerized device, it is important to acknowledge several study 
limitations. The mechanical handgrip did not provide feedback to participants regarding their 
ability to maintain 30% MVC (e.g., squeezing too hard or not hard enough). Therefore, 
participants may have been exerting more (or less) than the target intensity. This may have 
resulted in participants being able to achieve the same stimulus at a lower exercise intensity.  
Another limitation to this investigation was the inherit design differences of the two 
devices. The computerized device utilizes a force transducer within the handle, which provides 
little resistance to the participant. In contrast, the mechanical device utilizes a spring in order to 
generate resistance.  
Significance and Future Directions 
 The findings of this study appear to be promising as they suggest that a cost-effective 
mechanical device may be a similar stimulus to the traditional computerized dynamometer. 
However, due to the low observed power from this study, the findings should be interpreted with 
caution and future studies should aim to replicate these acute findings in a large-scale, 
adequately powered investigation, and determine the effects of training.  
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Appendix A: Recruitment Poster and Email Template:  
  
Do you think you have normal blood pressure?  
  
If so, you may be eligible to participate in a study examining the effects of a bout of handgrip 
exercise on blood pressure, heart rate and muscular activity of the arm using a computerized 
handgrip device vs a mechanical handgrip device. This study requires about 3 hours of your 
time split over 2 days (~0.5 hours for day 1 and ~2.5 hours for day 2) 
If you are interested and would like more information, please call: (519) ‐253‐3000  
ext. 4979 or email: uwhandgrip@gmail.com  
  
This study has been cleared by the University of Windsor’s Research Ethics Board  
 
 
  
  
Email/Class recruitment script:  
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"Attention anyone between the age of 18 and 30 years. If you think you have normal blood 
pressure, you may be eligible to participate in a research study being conducted by researchers at 
the University of Windsor. We are investigating the effects of isometric handgrip exercise on 
your blood pressure, heart rate and arm muscles. For more information please contact Nic or at 
519‐253‐3000 ex. 4979 or caruanan@uwindsor.ca” 
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Appendix B: Computerized Handgrip Device  
  
  
  
  
  
Computerized Digital Dynamometer (IBX H‐101, Zona Health, Boise, ID, USA)  
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Appendix C: Mechanical Handgrip Device   
  
  
  
  
Mechanical Handgrip (Item code: 239247305, www.dhgate.com) 
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Appendix D: Informed Consent            
   
  
 
CONSENT TO PARTICIPATE IN RESEARCH  
  
Title of Study: Comparative analysis of a bout of isometric hand grip using a traditional 
(computerized) or mechanical handgrip  
  
You are asked to participate in a research study conducted by Mr. Nic Caruana from the Faculty 
of Human Kinetics at the University of Windsor.  
  
If you have any questions or concerns about the research, please feel to contact co-
investigators Dr. Kevin Milne, PhD (kjmilne@uwindsor.ca), Dave Andrews, PhD 
(dandrews@uwindsor.ca) or Cheri McGowan, PhD (mcgowanc@uwindsor.ca).  
 
PURPOSE OF THE STUDY  
Our research group has shown that isometric (constant squeeze) exercise training using a 
computerized handgrip (isometric handgrip, IHG) lowers resting blood pressure (BP) in younger 
and older people, and in those with and without high BP. The computerized IHG is very expensive, 
and so we would like to see if an inexpensive mechanical handgrip that you can buy at the store 
may work just as well. Before we can do that, we need to figure out if the mechanical IHG causes 
your body to respond the same way as the computerized one.   
  
In order to participate in this study, you must have BP (<135/85 mmHg), and you must be between 
the ages of 18-30 years old. If you have a disorder or any known ailments or are taking any 
medications that influence your cardiovascular system (other than the birth control pill) you may 
be ineligible to participate. If you have a physical limitation impairing your ability to exercise you 
may also be ineligible to participate.   
 
PROCEDURES  
If you volunteer to participate in this study, you will attend the following:  
  
Visit 1 (approximately 30 minutes):  
You will meet with the study investigators at the Physical Activity and Cardiovascular Research 
(PACR) Laboratory (Room #240, Human Kinetics Building, University of Windsor, Windsor, 
Ontario, Canada) where you will receive a consent form and information sheet about the study. 
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At this time, one of the study investigators will explain all parts of the study. If you are still 
interested in participating in the study, you will sign the consent form and fill out brief medical 
questionnaires. If you are still eligible to participate, you will then have your BP measured in your 
upper arm, similar to how it is taken at a doctor’s office in brief, your resting BP will be measured 
in your upper dominant arm after 10 minutes of seated rest. Your BP will be measured 4 times, 
with 2 minutes of rest between measures. If you are eligible to participate, you will then have an 
opportunity to practice all parts of the study.  
 
Visit 2 (approximately 1 hour):  
At least 24 hours after visit 1, you will meet with the study investigators for a familiarization 
session. You will be asked to have refrained from vigorous physical activity over the previous 24 
hours, will be tested 2 hours post‐prandial and at least 12 hours post‐caffeine. To minimize the 
effects of a full bladder on BP, participants will be asked to void prior to familiarization session. 
If you are still interested in being a participant, you will be asked to provide on-going consent by 
initialling the visit 2 consent section of the consent form.  
 
You will then be given 10 minutes of seated rest after which 4 resting blood pressure values will 
be taken. You will be seated for the duration of the familiarization period, with both your right 
and left forearms resting on a table in front of you at an approximate 90‐degree angle. You will 
be outfitted with the necessary equipment to measure your BP, heart rate (HR) and electrical 
activity of the muscles through electromyography (EMG).  
 
You will then be asked to perform 3 maximal 2 second squeezes separated by 1-minute rest 
between squeezes on either the computerized handgrip device or the mechanical handgrip device. 
Following the third squeeze you will complete one 2-minute sustained squeeze at an intensity of 
30 % of your hardest squeeze during which blood pressure and heart rate measurements will be 
taken each minute. After you have completed the 2-minute squeeze, you will be asked to rate how 
much you feel you exerted yourself on a Borg 6-20 rating of perceived exertion scale, as well as 
asked to rank any discomfort that they may experience on a 1-10 numeric pain scale.  
 
You will then be given a 10-minute rest period and then will be asked to complete the same 
protocol utilizing the other handgrip device. Once completed if the you are still interested in 
engaging in the study, visit 3 will be scheduled at least 24 hours after this session. 
  
Visit 3 (approximately 2.5 hours):  
If you are still interested in participating in the study, you will visit the lab at least 24 hours 
following Visit 1.    
  
You will be asked not to exercise vigorously (e.g., exercise that causes you to breath really hard 
and sweat heavily) for 24 hours before the testing day, and to avoid caffeine for at least 12 hours 
before. All testing will take place in the morning at least 2 hours following your last meal, in a 
quiet, temperature‐controlled room. You will be asked to go to the washroom before testing, as a 
full bladder can increase your BP.  
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You will be seated for the duration of the testing period, with both your right and left forearms 
resting on a table in front of you at an approximate 90‐degree angle. You will be outfitted with 
the necessary equipment to measure your BP, heart rate (HR) and electrical activity of the muscles 
through electromyography (EMG). These measures will be collected continuously for 10 minutes 
prior to, during, and for at least 30 minutes following each IHG bout. Specifically, BP will be 
measured each minute using the device described above. Beat‐to‐beat HR will be acquired via 
standard 3‐lead echocardiography (ECG) for later calculation of HR and offline assessment of its 
variability (heart rate variability, an indirect assessment of the nervous system). On your non-
dominant arm, EMG data will be obtained by attaching two electrodes to the largest part of each 
muscle, parallel to the primary fascicle direction of the following arm muscles: forearm muscles 
- flexor carpi ulnaris, brachioradialis, extensor carpi ulnaris, brevis/longus; upper arm muscles - 
biceps brachii (“biceps”) and triceps brachii (“triceps”). The skin to which the electrodes will be 
attached will be shaved with a disposable safety razor (if needed) and then cleaned with an alcohol 
swab prior to attaching the electrodes. A low allergy surgical tape will be placed over the 
electrodes and adhered to the skin to minimize movement during testing.   
 
 
 
Next, you will be given 10 minutes of seated rest. Following the rest period, BP measurements 
will be taken in order to establish your baseline measurements. Following these measurements, 
your maximum voluntary contraction (MVC; hardest squeeze) will be calculated using each 
handgrip (traditional, computerized IHG and store‐bought mechanical IHG) in order to 
determine the intensity to which the IHG bouts will be performed.  
  
Next, you will be asked perform, in random order, an IHG protocol on the traditional, 
computerized IHG dynamometer and the store‐bought mechanical grip. The protocols will be 
separated by a 30-minute rest period (minimum) or until your BP has returned to near pre‐exercise 
values. During the 30-minute rest period you will have your blood pressure taken every 5 minutes 
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to make sure your BP is returning to pre-exercising values. In both conditions, the IHG bout will 
consist of four, 2‐minute unilateral (non‐dominant arm) contractions at 30% of the MVC, each 
separated by 4‐minute rest period. Following each 2-minute contraction, you will be asked to rate 
your level of perceived exertion using a 6-20 scale as well as rate any discomfort that you may be 
feeling on a 1-10 scale. Upon completion of the final bout of handgrip, there will a final 
stabilization period to ensure that your BP returns to near pre‐exercise values. Finally, upon 
completion of the final 30- minute rest period, you will be asked to state which handgrip device 
you preferred.  
 
POTENTIAL RISKS AND DISCOMFORTS  
You may experience numbness and/or tingling in the limb while the BP cuff inflates but this 
should disappear when the cuff is released. The sticker‐electrodes used to measure your HR and 
muscle activity may cause a skin irritation however, this risk is minimal. Tendonitis is possible 
from the IHG bouts, but as this occurs during a single session (and not for a training intervention) 
and proper technique will be enforced by study investigators during the session, this risk is 
minimal.   
  
Please contact one of the study investigators if you feel any adverse effects from completing any 
portion of the study, and/or if you have any questions or concerns. If you experience any adverse 
effects during any testing procedure, first line response will be provided.  
 
POTENTIAL BENEFITS TO PARTICIPANTS AND/OR TO SOCIETY  
You may not experience any physical direct benefit by participating in this single session study. 
However, if we prove our theories, evidence of the equivalence of a mechanical handgrip in 
comparison to the traditional, more expensive computerized IHG may lay the groundwork for 
future studies investigating the use of affordable, commercially available handgrips as a means to 
lower BP 
 
COMPENSATION FOR PARTICIPATION  
All participants will receive a Kinesiology Research T‐shirt upon their completion of the study.  
 
CONFIDENTIALITY  
Any information that is obtained in connection with this study that can identify you will remain 
confidential. 
  
To ensure your confidentiality, following your consent, you will be assigned an identification 
number. Your name will not be mentioned in any publication or presentation, and you will be 
identified with only your identification number on all collection tools (electronic or otherwise). 
All paper data will be stored in the locked laboratory (PACR Lab, Room #240, Human Kinetics 
Building, University of Windsor). Information stored on computer will be password‐accessible 
only. With respect to final disposal, all paper records (including medical and physical activity 
readiness questionnaires) will be shredded after 5 years.  
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PARTICIPATION AND WITHDRAWAL  
You can choose whether to be in this study or not, and your participation or lack of it will not 
influence your participation in another study. If you volunteer to be in this study, you may 
withdraw at any time without consequences of any kind. You may also refuse to answer any 
questions you do not wish to answer and still remain in the study. The investigator may withdraw 
you from this research if circumstances arise which warrant doing so. In any of the cases described 
above, you will still receive a Kinesiology Research T‐Shirt.  
 
FEEDBACK OF THE RESULTS OF THIS STUDY TO THE PARTICIPANTS  
Results of the study will be posted on the University of Windsor’s Research Ethics Board (REB) 
website (http://www.uwindsor.ca/reb) at the completion of the study.  
 
SUBSEQUENT USE OF DATA  
These data may be used in subsequent studies, in publications and in presentations however your 
privacy will be upheld with the use of your unique subject identification number under all 
circumstances. Data may be used as a foundation for future study of store‐bought, readily 
available IHG, and/or merged with other data sets for comparison. 
 
RIGHTS OF RESEARCH PARTICIPANTS  
If you have questions regarding your rights as a research participant, contact:  Research Ethics 
Coordinator, University of Windsor, Windsor, Ontario, N9B 3P4; Telephone: 519-253-3000, ext. 
3948; e-mail:  ethics@uwindsor.ca 
 
SIGNATURE OF RESEARCH PARTICIPANT/LEGAL REPRESENTATIVE  
I understand the information provided for the study: Comparative analysis of an acute bout of 
isometric hand grip using a traditional (computerized) or mechanical handgrip as described 
herein.  My questions have been answered to my satisfaction, and I agree to participate in this 
study.  I have been given a copy of this form.  
  
______________________________________  
Name of Participant  
  
______________________________________      ___________________  
Signature of Participant            Date  
  
 
Ongoing consent for Visit 2: 
 
 
________________       ____________________ 
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Initial of Participant       Date  
 
Ongoing consent for Visit 3: 
 
 
________________       ____________________ 
Initial of Participant       Date  
 
SIGNATURE OF INVESTIGATOR  
These are the terms under which I will conduct research.  
  
_____________________________________      ____________________  
Signature of Investigator            Date  
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 Appendix E: Letter of Information  
  
LETTER OF INFORMATION FOR CONSENT TO PARTICIPATE IN RESEARCH  
  
Title of Study: Comparative analysis of a bout of isometric hand grip using a traditional 
(computerized) or mechanical handgrip  
  
You are asked to participate in a research study conducted by Mr. Nic Caruana from the Faculty 
of Human Kinetics at the University of Windsor.  
  
If you have any questions or concerns about the research, please feel to contact co-
investigators Dr. Kevin Milne, PhD (kjmilne@uwindsor.ca), Dave Andrews, PhD 
(dandrews@uwindsor.ca) or Cheri McGowan, PhD (mcgowanc@uwindsor.ca).  
  
PURPOSE OF THE STUDY  
Our research group has shown that isometric (constant squeeze) exercise training using a 
computerized handgrip (isometric handgrip, IHG) lowers resting blood pressure (BP) in younger 
and older people, and in those with and without high BP. The computerized IHG is very 
expensive, and so we would like to see if an inexpensive mechanical handgrip that you can buy 
at the store may work just as well. Before we can do that, we need to figure out if the mechanical 
IHG causes your body to respond the same way as the computerized one.   
  
In order to participate in this study, you must have BP (<135/85 mmHg), and you must be 
between the ages of 18-30 years old. If you have a disorder or any known ailments or are taking 
any medications that influence your cardiovascular system (other than the birth control pill) you 
may be ineligible to participate. If you have a physical limitation impairing your ability to 
exercise you may also be ineligible to participate.   
  
PROCEDURES  
If you volunteer to participate in this study, you will attend the following:  
  
Visit 1 (approximately 30 minutes):  
You will meet with the study investigators at the Physical Activity and Cardiovascular Research 
(PACR) Laboratory (Room #240, Human Kinetics Building, University of Windsor, Windsor, 
Ontario, Canada) where you will receive a consent form and information sheet about the study. 
 99 
 
At this time, one of the study investigators will explain all parts of the study. If you are still 
interested in participating in the study, you will sign the consent form and fill out brief medical 
questionnaires. If you are still eligible to participate, you will then have your BP measured in 
your upper arm, similar to how it is taken at a doctor’s office in brief, your resting BP will be 
measured in your upper dominant arm after 10 minutes of seated rest. Your BP will be measured 
4 times, with 2 minutes of rest between measures. If you are eligible to participate, you will then 
have an opportunity to practice all parts of the study.  
 
Visit 2 (approximately 1 hour):  
At least 24 hours after visit 1, you will meet with the study investigators for a familiarization 
session. You will be asked to have refrained from vigorous physical activity over the previous 24 
hours, will be tested 2 hours post‐prandial and at least 12 hours post‐caffeine. To minimize the 
effects of a full bladder on BP, participants will be asked to void prior to familiarization session. 
If you are still interested in being a participant, you will be asked to provide on-going consent by 
initialling the visit 2 consent section of the consent form.  
 
You will then be given 10 minutes of seated rest after which 4 resting blood pressure values will 
be taken. You will be seated for the duration of the familiarization period, with both your right 
and left forearms resting on a table in front of you at an approximate 90‐degree angle. You will 
be outfitted with the necessary equipment to measure your BP, heart rate (HR) and electrical 
activity of the muscles through electromyography (EMG).  
 
You will then be asked to perform 3 maximal 2 second squeezes separated by 1-minute rest 
between squeezes on either the computerized handgrip device or the mechanical handgrip 
device. Following the third squeeze you will complete one 2-minute sustained squeeze at an 
intensity of 30 % of your hardest squeeze during which blood pressure and heart rate 
measurements will be taken each minute. After you have completed the 2-minute squeeze, you 
will be asked to rate how much you feel you exerted yourself on a Borg 6-20 rating of perceived 
exertion scale, as well as asked to rank any discomfort that they may experience on a 1-10 
numeric pain scale.  
 
You will then be given a 10-minute rest period and then will be asked to complete the same 
protocol utilizing the other handgrip device. Once completed if the you are still interested in 
engaging in the study, visit 3 will be scheduled at least 24 hours after this session. 
  
Visit 3 (approximately 2.5 hours):  
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If you are still interested in participating in the study, you will visit the lab at least 24 hours 
following Visit 1.    
  
You will be asked not to exercise vigorously (e.g., exercise that causes you to breath really hard 
and sweat heavily) for 24 hours before the testing day, and to avoid caffeine for at least 12 hours 
before. All testing will take place in the morning at least 2 hours following your last meal, in a 
quiet, temperature‐controlled room. You will be asked to go to the washroom before testing, as a 
full bladder can increase your BP If you are still interested in being a participant, you will be 
asked to provide on-going consent by initialling the visit 3 consent section of the consent form.  
  
You will be seated for the duration of the testing period, with both your right and left forearms 
resting on a table in front of you at an approximate 90‐degree angle. You will be outfitted with 
the necessary equipment to measure your BP, heart rate (HR) and electrical activity of the 
muscles through electromyography (EMG). These measures will be collected continuously for 
10 minutes prior to, during, and for at least 30 minutes following each IHG bout. Specifically, 
BP will be measured each minute using the device described above. Beat‐to‐beat HR will be 
acquired via standard 3‐lead echocardiography (ECG) for later calculation of HR and offline 
assessment of its variability (heart rate variability, an indirect assessment of the nervous system). 
On your non-dominant arm, EMG data will be obtained by attaching two electrodes to the largest 
part of each muscle, parallel to the primary fascicle direction of the following arm muscles: 
forearm muscles - flexor carpi ulnaris, brachioradialis, extensor carpi ulnaris, brevis/longus; 
upper arm muscles - biceps brachii (“biceps”) and triceps brachii (“triceps”). The skin to which 
the electrodes will be attached will be shaved with a disposable safety razor (if needed) and then 
cleaned with an alcohol swab prior to attaching the electrodes. A low allergy surgical tape will 
be placed over the electrodes and adhered to the skin to minimize movement during testing.   
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Next, you will be given 10 minutes of seated rest. Following the rest period, BP measurements 
will be taken in order to establish your baseline measurements. Following these measurements, 
your maximum voluntary contraction (MVC; hardest squeeze) will be calculated using each 
handgrip (traditional, computerized IHG and store‐bought mechanical IHG) in order to 
determine the intensity to which the IHG bouts will be performed.  
  
Next, you will be asked perform, in random order, an IHG protocol on the traditional, 
computerized IHG dynamometer and the store‐bought mechanical grip. The protocols will be 
separated by a 30-minute rest period (minimum) or until your BP has returned to near pre‐
exercise values. During the 30-minute rest period you will have your blood pressure taken every 
5 minutes to make sure your BP is returning to pre-exercising values. In both conditions, the IHG 
bout will consist of four, 2‐minute unilateral (non‐dominant arm) contractions at 30% of the 
MVC, each separated by 4‐minute rest period. Following each 2-minute contraction, you will be 
asked to rate your level of perceived exertion using a 6-20 scale as well as rate any discomfort 
that you may be feeling on a 1-10 scale. Upon completion of the final bout of handgrip, there 
will a final stabilization period to ensure that your BP returns to near pre‐exercise values. 
Finally, upon completion of the final 30- minute rest period, you will be asked to state which 
handgrip device you preferred.  
  
POTENTIAL RISKS AND DISCOMFORTS  
You may experience numbness and/or tingling in the limb while the BP cuff inflates but this 
should disappear when the cuff is released. The sticker‐electrodes used to measure your HR and 
muscle activity may cause a skin irritation however, this risk is minimal. Tendonitis is possible 
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from the IHG bouts, but as this occurs during a single session (and not for a training 
intervention) and proper technique will be enforced by study investigators during the session, 
this risk is minimal.   
  
Please contact one of the study investigators if you feel any adverse effects from completing any 
portion of the study, and/or if you have any questions or concerns. If you experience any adverse 
effects during any testing procedure, first line response will be provided.  
   
POTENTIAL BENEFITS TO PARTICIPANTS AND/OR TO SOCIETY  
You may not experience any physical direct benefit by participating in this single session study. 
However, if we prove our theories, evidence of the equivalence of a mechanical handgrip in 
comparison to the traditional, more expensive computerized IHG may lay the groundwork for 
future studies investigating the use of affordable, commercially available handgrips as a means to 
lower BP 
  
COMPENSATION FOR PARTICIPATION  
All participants will receive a Kinesiology Research T‐shirt upon their completion of the study.  
  
CONFIDENTIALITY  
Any information that is obtained in connection with this study that can identify you will remain 
confidential. 
  
To ensure your confidentiality, following your consent, you will be assigned an identification 
number. Your name will not be mentioned in any publication or presentation, and you will be 
identified with only your identification number on all collection tools (electronic or otherwise). 
All paper data will be stored in the locked laboratory (PACR Lab, Room #240, Human Kinetics 
Building, University of Windsor). Information stored on computer will be password‐accessible 
only. With respect to final disposal, all paper records (including medical and physical activity 
readiness questionnaires) will be shredded after 5 years.  
 
PARTICIPATION AND WITHDRAWAL  
You can choose whether to be in this study or not, and your participation or lack of it will not 
influence your participation in another study. If you volunteer to be in this study, you may 
withdraw at any time without consequences of any kind. You may also refuse to answer any 
questions you do not wish to answer and still remain in the study. The investigator may withdraw 
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you from this research if circumstances arise which warrant doing so. In any of the cases 
described above, you will still receive a Kinesiology Research T‐Shirt.  
  
FEEDBACK OF THE RESULTS OF THIS STUDY TO THE PARTICIPANTS  
Results of the study will be posted on the University of Windsor’s Research Ethics Board (REB) 
website (http://www.uwindsor.ca/reb) at the completion of the study.  
 
SUBSEQUENT USE OF DATA  
These data may be used in subsequent studies, in publications and in presentations however your 
privacy will be upheld with the use of your unique subject identification number under all 
circumstances. Data may be used as a foundation for future study of store‐bought, readily 
available IHG, and/or merged with other data sets for comparison. 
 
RIGHTS OF RESEARCH PARTICIPANTS  
If you have questions regarding your rights as a research participant, contact:  Research Ethics 
Coordinator, University of Windsor, Windsor, Ontario, N9B 3P4; Telephone: 519-253-3000, ext. 
3948; e-mail:  ethics@uwindsor.ca 
 
SIGNATURE OF INVESTIGATOR  
These are the terms under which I will conduct research.  
 
  
_____________________________________      ____________________  
Signature of Investigator            Date  
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Appendix F: Intake Medical Questionnaire and Physical Activity Readiness Questionnaire 
(PAR-Q)  
Participant code: ____________ 
Height: _______________________ Mass: _______________________ Date of Birth 
(Month/Yr) ___________________________________   
Phone  (             ) _______________________________  Postal Code ________________ 
  
FOR EMERGENCY NOTIFY:  Name__________ 
   Relationship ______________ 
  
Address _______________________________________________  Phone
______________________________________________________ 
Family Doctor's Name _____________________________   
Date of Last Physical  __________________________ 
 
Please Check: Yes or No          
 
                                                                                              Yes No  
1. Have you ever been hospitalized?                                                                               
  If yes, please specify? 
___________________________________________________________________________
____________ 
  
Have you ever had surgery?                                                                                               
          
       If yes, please specify? 
______________________________________________________________________________
_________ 
 
2. Are you presently taking any medications or pills (including aspirin and other over the-counter 
medication)?                                                                                                         
   
 
    If yes, please specify?   
______________________________________________________________________________
________ 
 
 Are you presently taking any vitamins, supplements, and/or herbal supplements?   
   
3. Do you have any allergies (medicine, food, bees or other stinging insects)?                   
 
     If yes, please specify? 
______________________________________________________________________________
_________  
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4. Have you ever passed out during or after exercise?                                                            
  
Have you ever been dizzy during or after exercise?                                                                
  
  Have you ever had chest pain during or after exercise?                                                         
                                                                                                       Yes No 
  Do you have high blood pressure (hypertension) or  
  low blood pressure (hypotension)?   
                                                                                                                                              
        
 Have you ever been told that you have a kidney problem?                                                      
 
 Have you ever been told that you have joint instability?                                                          
 
 Have you ever been told that you have a stomach problem?                                                    
        
 Have you ever been told that you have a heart problem?                                                         
       
Have you ever been told that you have a heart murmur?                                                           
  
 Do you have a machine that regulated your heart beat?    
                                                                                                                                                    
 Have you ever had racing of your heart or skipped heartbeats?      
                                                                                                                                                        
 Has anyone in your family died of heart problems or a  
 sudden death before age 50? 
                                                                                                                                                    
5. Do you have any skin problems (itching, rashes, acne)?                                                     
       
 If you get a cut, does it take you a long time to stop bleeding?                                                 
  
If you experience a blow to a muscle, do you bruise easily?                                                     
 
6. Do you have Diabetes?                                                                                                         
 
7. Do you have Asthma or any other breathing problems?                                                            
        If yes, please specify? 
______________________________________________________________________________
_________ 
 
8. Do you have any type of cardiovascular disease?                                                                   
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      If yes, please specify? 
______________________________________________________________________________
_________ 
 
 9. Have you had any other medical problems (infectious mononucleosis, etc.)?  
                                                                                                                                                     
                                                                                                                                 
10. Have you had any medical problems since your last physical?                                            
 
11. Do you smoke?                                                                                                                      
 
 12. Do you aerobically exercise (e.g., walking) for                                                      
        > 30 minutes, > 2 times per week? 
                                                                                                               
13.  Do you currently take any birth control medications?                                                                    
 
        If yes, please specify? 
______________________________________________________________________________
_________ 
 
14. Date of last menstrual cycle_____________________________________________ 
Please explain any physical limitations that may prevent you from completing this study: 
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Appendix G: Blood Pressure Oscillometric Device  
 
  
  
  
  
(Dinamap Carescape v100, Critikon, Tampa, Florida, USA)  
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Appendix H: EMG Equipment and Electrodes 
 
(PUN-96, Bortec Biological Limited, Calgary, Alberta, Canada) 
 
 
(Covidien llc. Mansfield, MA, USA) 
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Appendix I: Borg Rating of Perceived Exertion Scale (RPE) 
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Appendix J: Pain Assessment: Numerical Rating Scale for Pain (NRS Pain) 
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Appendix K: Statistical Data for Chapter 2 
 
1. SBP (All Effects)  
Tests of Within-Subjects Effects 
Measure:   MEASURE_1   
Source 
Type III 
Sum of 
Squares df 
Mean 
Square F Sig. 
Device Sphericit
y 
Assumed 
762.066 1 762.066 2.798 .113 
Greenho
use-
Geisser 
762.066 1.000 762.066 2.798 .113 
Huynh-
Feldt 
762.066 1.000 762.066 2.798 .113 
Lower-
bound 
762.066 1.000 762.066 2.798 .113 
Device * SEX Sphericit
y 
Assumed 
1255.811 1 1255.81
1 
4.610 .047 
Greenho
use-
Geisser 
1255.811 1.000 1255.81
1 
4.610 .047 
Huynh-
Feldt 
1255.811 1.000 1255.81
1 
4.610 .047 
Lower-
bound 
1255.811 1.000 1255.81
1 
4.610 .047 
Device * 
Device_Starting_Ord
er 
Sphericit
y 
Assumed 
23.131 1 23.131 .085 .774 
Greenho
use-
Geisser 
23.131 1.000 23.131 .085 .774 
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Huynh-
Feldt 
23.131 1.000 23.131 .085 .774 
Lower-
bound 
23.131 1.000 23.131 .085 .774 
Error(Device) Sphericit
y 
Assumed 
4630.891 17 272.405 
  
Greenho
use-
Geisser 
4630.891 17.000 272.405 
  
Huynh-
Feldt 
4630.891 17.000 272.405 
  
Lower-
bound 
4630.891 17.000 272.405 
  
Contraction Sphericit
y 
Assumed 
63.998 3 21.333 .230 .875 
Greenho
use-
Geisser 
63.998 1.888 33.902 .230 .783 
Huynh-
Feldt 
63.998 2.366 27.049 .230 .830 
Lower-
bound 
63.998 1.000 63.998 .230 .637 
Contraction * SEX Sphericit
y 
Assumed 
412.972 3 137.657 1.486 .229 
Greenho
use-
Geisser 
412.972 1.888 218.764 1.486 .241 
Huynh-
Feldt 
412.972 2.366 174.547 1.486 .237 
Lower-
bound 
412.972 1.000 412.972 1.486 .239 
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Contraction * 
Device_Starting_Ord
er 
Sphericit
y 
Assumed 
302.939 3 100.980 1.090 .362 
Greenho
use-
Geisser 
302.939 1.888 160.476 1.090 .345 
Huynh-
Feldt 
302.939 2.366 128.040 1.090 .354 
Lower-
bound 
302.939 1.000 302.939 1.090 .311 
Error(Contraction) Sphericit
y 
Assumed 
4723.402 51 92.616 
  
Greenho
use-
Geisser 
4723.402 32.092 147.184 
  
Huynh-
Feldt 
4723.402 40.221 117.435 
  
Lower-
bound 
4723.402 17.000 277.847 
  
Device * Contraction Sphericit
y 
Assumed 
355.040 3 118.347 1.308 .282 
Greenho
use-
Geisser 
355.040 1.785 198.856 1.308 .283 
Huynh-
Feldt 
355.040 2.216 160.252 1.308 .284 
Lower-
bound 
355.040 1.000 355.040 1.308 .269 
Device * Contraction 
* SEX 
Sphericit
y 
Assumed 
301.969 3 100.656 1.113 .353 
Greenho
use-
Geisser 
301.969 1.785 169.132 1.113 .336 
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Huynh-
Feldt 
301.969 2.216 136.298 1.113 .344 
Lower-
bound 
301.969 1.000 301.969 1.113 .306 
Device * Contraction 
* 
Device_Starting_Ord
er 
Sphericit
y 
Assumed 
242.194 3 80.731 .892 .451 
Greenho
use-
Geisser 
242.194 1.785 135.652 .892 .410 
Huynh-
Feldt 
242.194 2.216 109.317 .892 .427 
Lower-
bound 
242.194 1.000 242.194 .892 .358 
Error(Device*Contra
ction) 
Sphericit
y 
Assumed 
4613.551 51 90.462 
  
Greenho
use-
Geisser 
4613.551 30.352 152.002 
  
Huynh-
Feldt 
4613.551 37.664 122.493 
  
Lower-
bound 
4613.551 17.000 271.385 
  
 
Sex* Device interaction 
 
ANOVA 
SBP   
 
Sum of 
Squares df Mean Square F 
Between 
Groups 
2105.519 3 701.840 5.061 
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Within 
Groups 
21635.225 156 138.687 
 
Total 23740.744 159   
 
ANOVA 
SBP   
 Sig. 
Between Groups .002 
Within Groups  
Total  
 
 
Post Hoc Tests 
 
 
 
Multiple Comparisons 
Dependent Variable:   SBP   
Tukey HSD   
(I) Gender2 (J) Gender2 
Mean Difference 
(I-J) Std. Error Sig. 
Male Mech Male Comp 9.18182* 2.51077 .002 
Female 
Mech 
7.71717* 2.64658 .021 
Female 
Comp 
5.30051 2.64658 .191 
Male Comp Male Mech -9.18182* 2.51077 .002 
Female 
Mech 
-1.46465 2.64658 .946 
Female 
Comp 
-3.88131 2.64658 .460 
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Female 
Mech 
Male Mech -7.71717* 2.64658 .021 
Male Comp 1.46465 2.64658 .946 
Female 
Comp 
-2.41667 2.77576 .820 
Female 
Comp 
Male Mech -5.30051 2.64658 .191 
Male Comp 3.88131 2.64658 .460 
Female 
Mech 
2.41667 2.77576 .820 
 
Multiple Comparisons 
Dependent Variable:   SBP   
Tukey HSD   
(I) Gender2 (J) Gender2 
95% Confidence Interval 
Lower Bound Upper Bound 
Male Mech Male Comp 2.6615 15.7021 
Female Mech .8442 14.5902 
Female Comp -1.5725 12.1735 
Male Comp Male Mech -15.7021 -2.6615 
Female Mech -8.3377 5.4084 
Female Comp -10.7543 2.9917 
Female Mech Male Mech -14.5902 -.8442 
Male Comp -5.4084 8.3377 
Female Comp -9.6251 4.7918 
Female Comp Male Mech -12.1735 1.5725 
Male Comp -2.9917 10.7543 
Female Mech -4.7918 9.6251 
 
*. The mean difference is significant at the 0.05 level. 
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2. DBP (All Effects) 
Tests of Within-Subjects Effects 
Measure:   MEASURE_1   
Source 
Type III 
Sum of 
Squares df 
Mean 
Square F 
Sig. 
Device Spher
icity 
Assu
med 
1522.8
61 
1 1522.861 5.9
02 
.02
7 
Gree
nhou
se-
Geiss
er 
1522.8
61 
1.000 1522.861 5.9
02 
.02
7 
Huyn
h-
Feldt 
1522.8
61 
1.000 1522.861 5.9
02 
.02
7 
Lowe
r-
boun
d 
1522.8
61 
1.000 1522.861 5.9
02 
.02
7 
Device * SEX Spher
icity 
Assu
med 
1748.8
01 
1 1748.801 6.7
77 
.01
9 
Gree
nhou
se-
Geiss
er 
1748.8
01 
1.000 1748.801 6.7
77 
.01
9 
Huyn
h-
Feldt 
1748.8
01 
1.000 1748.801 6.7
77 
.01
9 
Lowe
r-
boun
d 
1748.8
01 
1.000 1748.801 6.7
77 
.01
9 
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Device * 
Device_Starting_
Order 
Spher
icity 
Assu
med 
670.92
5 
1 670.925 2.6
00 
.12
5 
Gree
nhou
se-
Geiss
er 
670.92
5 
1.000 670.925 2.6
00 
.12
5 
Huyn
h-
Feldt 
670.92
5 
1.000 670.925 2.6
00 
.12
5 
Lowe
r-
boun
d 
670.92
5 
1.000 670.925 2.6
00 
.12
5 
Error(Device) Spher
icity 
Assu
med 
4386.5
98 
17 258.035 
  
Gree
nhou
se-
Geiss
er 
4386.5
98 
17.000 258.035 
  
Huyn
h-
Feldt 
4386.5
98 
17.000 258.035 
  
Lowe
r-
boun
d 
4386.5
98 
17.000 258.035 
  
Contraction Spher
icity 
Assu
med 
261.82
0 
3 87.273 1.0
95 
.36
0 
Gree
nhou
se-
Geiss
er 
261.82
0 
2.026 129.204 1.0
95 
.34
7 
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Huyn
h-
Feldt 
261.82
0 
2.573 101.754 1.0
95 
.35
5 
Lowe
r-
boun
d 
261.82
0 
1.000 261.820 1.0
95 
.31
0 
Contraction * 
SEX 
Spher
icity 
Assu
med 
458.18
0 
3 152.727 1.9
16 
.13
9 
Gree
nhou
se-
Geiss
er 
458.18
0 
2.026 226.105 1.9
16 
.16
2 
Huyn
h-
Feldt 
458.18
0 
2.573 178.068 1.9
16 
.14
9 
Lowe
r-
boun
d 
458.18
0 
1.000 458.180 1.9
16 
.18
4 
Contraction * 
Device_Starting_
Order 
Spher
icity 
Assu
med 
138.51
1 
3 46.170 .57
9 
.63
1 
Gree
nhou
se-
Geiss
er 
138.51
1 
2.026 68.353 .57
9 
.56
8 
Huyn
h-
Feldt 
138.51
1 
2.573 53.831 .57
9 
.60
6 
Lowe
r-
boun
d 
138.51
1 
1.000 138.511 .57
9 
.45
7 
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Error(Contraction
) 
Spher
icity 
Assu
med 
4064.5
47 
51 79.697 
  
Gree
nhou
se-
Geiss
er 
4064.5
47 
34.449 117.988 
  
Huyn
h-
Feldt 
4064.5
47 
43.742 92.921 
  
Lowe
r-
boun
d 
4064.5
47 
17.000 239.091 
  
Device * 
Contraction 
Spher
icity 
Assu
med 
476.14
5 
3 158.715 1.6
99 
.17
9 
Gree
nhou
se-
Geiss
er 
476.14
5 
1.871 254.542 1.6
99 
.20
0 
Huyn
h-
Feldt 
476.14
5 
2.341 203.428 1.6
99 
.19
2 
Lowe
r-
boun
d 
476.14
5 
1.000 476.145 1.6
99 
.21
0 
Device * 
Contraction * 
SEX 
Spher
icity 
Assu
med 
171.29
3 
3 57.098 .61
1 
.61
1 
Gree
nhou
se-
Geiss
er 
171.29
3 
1.871 91.571 .61
1 
.53
8 
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Huyn
h-
Feldt 
171.29
3 
2.341 73.183 .61
1 
.57
2 
Lowe
r-
boun
d 
171.29
3 
1.000 171.293 .61
1 
.44
5 
Device * 
Contraction * 
Device_Starting_
Order 
Spher
icity 
Assu
med 
716.25
0 
3 238.750 2.5
56 
.06
5 
Gree
nhou
se-
Geiss
er 
716.25
0 
1.871 382.899 2.5
56 
.09
7 
Huyn
h-
Feldt 
716.25
0 
2.3
41 
306.011 2.5
56 
.08
2 
Lowe
r-
boun
d 
716.25
0 
1.0
00 
716.250 2.5
56 
.12
8 
Error(Device*Co
ntraction) 
Spher
icity 
Assu
med 
4763.3
08 
51 93.398 
  
Gree
nhou
se-
Geiss
er 
4763.3
08 
31.
80
0 
149.789 
  
Huyn
h-
Feldt 
4763.3
08 
39.
79
0 
119.710 
  
Lowe
r-
boun
d 
4763.3
08 
17.
00
0 
280.195 
  
 
Device * Sex interaction  
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ANOVA 
DBP   
 Sum of Squares df Mean Square F 
Between Groups 1506.266 3 502.089 3.331 
Within Groups 23516.977 156 150.750  
Total 25023.244 159   
 
ANOVA 
DBP   
 Sig. 
Between Groups .021 
Within Groups  
Total  
 
Post Hoc Tests 
Multiple Comparisons 
Dependent Variable:   DBP   
Tukey HSD   
(I) Gender2 (J) Gender2 
Mean Difference (I-
J) Std. Error Sig. 
Male Mech Male Comp 4.43182 2.61768 .331 
Female Mech 8.28030* 2.75928 .016 
Female Comp 1.78030 2.75928 .917 
Male Comp Male Mech -4.43182 2.61768 .331 
Female Mech 3.84848 2.75928 .505 
Female Comp -2.65152 2.75928 .772 
Female Mech Male Mech -8.28030* 2.75928 .016 
Male Comp -3.84848 2.75928 .505 
Female Comp -6.50000 2.89396 .116 
Female Comp Male Mech -1.78030 2.75928 .917 
Male Comp 2.65152 2.75928 .772 
Female Mech 6.50000 2.89396 .116 
 
Multiple Comparisons 
Dependent Variable:   DBP   
Tukey HSD   
(I) Gender2 (J) Gender2 
95% Confidence Interval 
Lower Bound Upper Bound 
Male Mech Male Comp -2.3661 11.2298 
Female Mech 1.1146 15.4460 
Female Comp -5.3854 8.9460 
Male Comp Male Mech -11.2298 2.3661 
Female Mech -3.3172 11.0142 
Female Comp -9.8172 4.5142 
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Female Mech Male Mech -15.4460 -1.1146 
Male Comp -11.0142 3.3172 
Female Comp -14.0154 1.0154 
Female Comp Male Mech -8.9460 5.3854 
Male Comp -4.5142 9.8172 
Female Mech -1.0154 14.0154 
 
*. The mean difference is significant at the 0.05 level. 
 
3. HR (All Effects) 
Tests of Within-Subjects Effects 
Measure:   MEASURE_1   
Source 
Type III Sum 
of Squares df 
Mean 
Square F Sig. 
Device Sphericity 
Assumed 
207.047 1 207.047 1.958 .180 
Greenhouse-
Geisser 
207.047 1.000 207.047 1.958 .180 
Huynh-Feldt 207.047 1.000 207.047 1.958 .180 
Lower-
bound 
207.047 1.000 207.047 1.958 .180 
Device * SEX Sphericity 
Assumed 
72.928 1 72.928 .690 .418 
Greenhouse-
Geisser 
72.928 1.000 72.928 .690 .418 
Huynh-Feldt 72.928 1.000 72.928 .690 .418 
Lower-
bound 
72.928 1.000 72.928 .690 .418 
Device * 
Device_Starting_Order 
Sphericity 
Assumed 
248.685 1 248.685 2.352 .144 
Greenhouse-
Geisser 
248.685 1.000 248.685 2.352 .144 
Huynh-Feldt 248.685 1.000 248.685 2.352 .144 
Lower-
bound 
248.685 1.000 248.685 2.352 .144 
Error(Device) Sphericity 
Assumed 
1797.714 17 105.748 
  
Greenhouse-
Geisser 
1797.714 17.000 105.748 
  
Huynh-Feldt 1797.714 17.000 105.748   
Lower-
bound 
1797.714 17.000 105.748 
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Contraction Sphericity 
Assumed 
42.861 3 14.287 .681 .568 
Greenhouse-
Geisser 
42.861 2.469 17.360 .681 .541 
Huynh-Feldt 42.861 3.000 14.287 .681 .568 
Lower-
bound 
42.861 1.000 42.861 .681 .421 
Contraction * SEX Sphericity 
Assumed 
35.288 3 11.763 .561 .643 
Greenhouse-
Geisser 
35.288 2.469 14.293 .561 .611 
Huynh-Feldt 35.288 3.000 11.763 .561 .643 
Lower-
bound 
35.288 1.000 35.288 .561 .464 
Contraction * 
Device_Starting_Order 
Sphericity 
Assumed 
34.793 3 11.598 .553 .649 
Greenhouse-
Geisser 
34.793 2.469 14.093 .553 .616 
Huynh-Feldt 34.793 3.000 11.598 .553 .649 
Lower-
bound 
34.793 1.000 34.793 .553 .467 
Error(Contraction) Sphericity 
Assumed 
1070.192 51 20.984 
  
Greenhouse-
Geisser 
1070.192 41.971 25.499 
  
Huynh-Feldt 1070.192 51.000 20.984   
Lower-
bound 
1070.192 17.000 62.952 
  
Device * Contraction Sphericity 
Assumed 
86.789 3 28.930 1.383 .258 
Greenhouse-
Geisser 
86.789 2.542 34.146 1.383 .262 
Huynh-Feldt 86.789 3.000 28.930 1.383 .258 
Lower-
bound 
86.789 1.000 86.789 1.383 .256 
Device * Contraction * 
SEX 
Sphericity 
Assumed 
56.221 3 18.740 .896 .450 
Greenhouse-
Geisser 
56.221 2.542 22.120 .896 .437 
Huynh-Feldt 56.221 3.000 18.740 .896 .450 
Lower-
bound 
56.221 1.000 56.221 .896 .357 
Device * Contraction * 
Device_Starting_Order 
Sphericity 
Assumed 
87.080 3 29.027 1.388 .257 
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Greenhouse-
Geisser 
87.080 2.542 34.261 1.388 .261 
Huynh-Feldt 87.080 3.000 29.027 1.388 .257 
Lower-
bound 
87.080 1.000 87.080 1.388 .255 
Error(Device*Contractio
n) 
Sphericity 
Assumed 
1066.612 51 20.914 
  
Greenhouse-
Geisser 
1066.612 43.209 24.685 
  
Huynh-Feldt 1066.612 51.000 20.914   
Lower-
bound 
1066.612 17.000 62.742 
  
 
4. BR EMG (All Effects) 
Tests of Within-Subjects Effects 
Measure:   MEASURE_1   
Source 
Type III Sum 
of Squares df 
Mean 
Square F Sig. 
HandgripDevice Sphericity 
Assumed 
1785.525 1 1785.525 3.845 .066 
Greenhouse-
Geisser 
1785.525 1.000 1785.525 3.845 .066 
Huynh-Feldt 1785.525 1.000 1785.525 3.845 .066 
Lower-
bound 
1785.525 1.000 1785.525 3.845 .066 
HandgripDevice * Sex Sphericity 
Assumed 
423.278 1 423.278 .912 .353 
Greenhouse-
Geisser 
423.278 1.000 423.278 .912 .353 
Huynh-Feldt 423.278 1.000 423.278 .912 .353 
Lower-
bound 
423.278 1.000 423.278 .912 .353 
HandgripDevice * 
Order_Starting_Device 
Sphericity 
Assumed 
243.147 1 243.147 .524 .479 
Greenhouse-
Geisser 
243.147 1.000 243.147 .524 .479 
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Huynh-Feldt 243.147 1.000 243.147 .524 .479 
Lower-
bound 
243.147 1.000 243.147 .524 .479 
Error(HandgripDevice) Sphericity 
Assumed 
7893.847 17 464.344 
  
Greenhouse-
Geisser 
7893.847 17.000 464.344 
  
Huynh-Feldt 7893.847 17.000 464.344   
Lower-
bound 
7893.847 17.000 464.344 
  
Contraction Sphericity 
Assumed 
164315.268 3 54771.756 2.474 .072 
Greenhouse-
Geisser 
164315.268 1.810 90764.900 2.474 .105 
Huynh-Feldt 164315.268 2.252 72964.854 2.474 .092 
Lower-
bound 
164315.268 1.000 164315.26
8 
2.474 .134 
Contraction * Sex Sphericity 
Assumed 
93406.283 3 31135.428 1.406 .252 
Greenhouse-
Geisser 
93406.283 1.810 51596.008 1.406 .259 
Huynh-Feldt 93406.283 2.252 41477.434 1.406 .258 
Lower-
bound 
93406.283 1.000 93406.283 1.406 .252 
Contraction * 
Order_Starting_Device 
Sphericity 
Assumed 
130363.904 3 43454.635 1.962 .131 
Greenhouse-
Geisser 
130363.904 1.810 72010.756 1.962 .161 
Huynh-Feldt 130363.904 2.252 57888.614 1.962 .150 
Lower-
bound 
130363.904 1.000 130363.90
4 
1.962 .179 
Error(Contraction) Sphericity 
Assumed 
1129269.365 51 22142.537 
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Greenhouse-
Geisser 
1129269.365 30.776 36693.458 
  
Huynh-Feldt 1129269.365 38.284 29497.446   
Lower-
bound 
1129269.365 17.000 66427.610 
  
HandgripDevice * 
Contraction 
Sphericity 
Assumed 
8998.987 3 2999.662 3.721 .017 
Greenhouse-
Geisser 
8998.987 2.457 3663.004 3.721 .025 
Huynh-Feldt 8998.987 3.000 2999.662 3.721 .017 
Lower-
bound 
8998.987 1.000 8998.987 3.721 .071 
HandgripDevice * 
Contraction * Sex 
Sphericity 
Assumed 
5250.664 3 1750.221 2.171 .103 
Greenhouse-
Geisser 
5250.664 2.457 2137.263 2.171 .117 
Huynh-Feldt 5250.664 3.000 1750.221 2.171 .103 
Lower-
bound 
5250.664 1.000 5250.664 2.171 .159 
HandgripDevice * 
Contraction * 
Order_Starting_Device 
Sphericity 
Assumed 
3628.272 3 1209.424 1.500 .226 
Greenhouse-
Geisser 
3628.272 2.457 1476.874 1.500 .233 
Huynh-Feldt 3628.272 3.000 1209.424 1.500 .226 
Lower-
bound 
3628.272 1.000 3628.272 1.500 .237 
Error(HandgripDevice*C
ontraction) 
Sphericity 
Assumed 
41117.455 51 806.225 
  
Greenhouse-
Geisser 
41117.455 41.764 984.512 
  
Huynh-Feldt 41117.455 51.000 806.225   
Lower-
bound 
41117.455 17.000 2418.674 
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5. BB EMG (All Effects) 
 
Tests of Within-Subjects Effects 
Measure:   MEASURE_1   
Source 
Type III Sum 
of Squares df 
Mean 
Square F Sig. 
HandgripDevice Sphericity 
Assumed 
5899.436 1 5899.436 6.410 .021 
Greenhouse-
Geisser 
5899.436 1.000 5899.436 6.410 .021 
Huynh-Feldt 5899.436 1.000 5899.436 6.410 .021 
Lower-
bound 
5899.436 1.000 5899.436 6.410 .021 
HandgripDevice * Sex Sphericity 
Assumed 
3255.171 1 3255.171 3.537 .077 
Greenhouse-
Geisser 
3255.171 1.000 3255.171 3.537 .077 
Huynh-Feldt 3255.171 1.000 3255.171 3.537 .077 
Lower-
bound 
3255.171 1.000 3255.171 3.537 .077 
HandgripDevice * 
Order_Starting_Device 
Sphericity 
Assumed 
2600.764 1 2600.764 2.826 .111 
Greenhouse-
Geisser 
2600.764 1.000 2600.764 2.826 .111 
Huynh-Feldt 2600.764 1.000 2600.764 2.826 .111 
Lower-
bound 
2600.764 1.000 2600.764 2.826 .111 
Error(HandgripDevice) Sphericity 
Assumed 
15645.643 17 920.332 
  
Greenhouse-
Geisser 
15645.643 17.000 920.332 
  
Huynh-Feldt 15645.643 17.000 920.332   
Lower-
bound 
15645.643 17.000 920.332 
  
Contraction Sphericity 
Assumed 
801034.265 3 267011.42
2 
4.393 .008 
Greenhouse-
Geisser 
801034.265 1.007 795632.15
0 
4.393 .051 
Huynh-Feldt 801034.265 1.134 706399.13
8 
4.393 .045 
 130 
 
Lower-
bound 
801034.265 1.000 801034.26
5 
4.393 .051 
Contraction * Sex Sphericity 
Assumed 
459909.937 3 153303.31
2 
2.522 .068 
Greenhouse-
Geisser 
459909.937 1.007 456808.33
9 
2.522 .130 
Huynh-Feldt 459909.937 1.134 405575.63
8 
2.522 .126 
Lower-
bound 
459909.937 1.000 459909.93
7 
2.522 .131 
Contraction * 
Order_Starting_Device 
Sphericity 
Assumed 
477939.820 3 159313.27
3 
2.621 .061 
Greenhouse-
Geisser 
477939.820 1.007 474716.63
0 
2.621 .124 
Huynh-Feldt 477939.820 1.134 421475.44
9 
2.621 .119 
Lower-
bound 
477939.820 1.000 477939.82
0 
2.621 .124 
Error(Contraction) Sphericity 
Assumed 
3099652.686 51 60777.504 
  
Greenhouse-
Geisser 
3099652.686 17.115 181102.87
4 
  
Huynh-Feldt 3099652.686 19.277 160791.53
4 
  
Lower-
bound 
3099652.686 17.000 182332.51
1 
  
HandgripDevice * 
Contraction 
Sphericity 
Assumed 
25709.080 3 8569.693 5.002 .004 
Greenhouse-
Geisser 
25709.080 1.076 23897.253 5.002 .036 
Huynh-Feldt 25709.080 1.226 20977.085 5.002 .030 
Lower-
bound 
25709.080 1.000 25709.080 5.002 .039 
HandgripDevice * 
Contraction * Sex 
Sphericity 
Assumed 
15212.922 3 5070.974 2.960 .041 
Greenhouse-
Geisser 
15212.922 1.076 14140.803 2.960 .100 
Huynh-Feldt 15212.922 1.226 12412.842 2.960 .094 
Lower-
bound 
15212.922 1.000 15212.922 2.960 .103 
HandgripDevice * 
Contraction * 
Order_Starting_Device 
Sphericity 
Assumed 
11990.838 3 3996.946 2.333 .085 
Greenhouse-
Geisser 
11990.838 1.076 11145.793 2.333 .143 
Huynh-Feldt 11990.838 1.226 9783.813 2.333 .138 
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Lower-
bound 
11990.838 1.000 11990.838 2.333 .145 
Error(HandgripDevice*C
ontraction) 
Sphericity 
Assumed 
87369.323 51 1713.124 
  
Greenhouse-
Geisser 
87369.323 18.289 4777.179 
  
Huynh-Feldt 87369.323 20.835 4193.423   
Lower-
bound 
87369.323 17.000 5139.372 
  
 
 
6. ECU EMG (All Effects) 
Tests of Within-Subjects Effects 
Measure:   MEASURE_1   
Source 
Type 
III 
Sum 
of 
Square
s df 
M
ea
n 
Sq
ua
re F 
Si
g. 
HandgripDevice Spher
icity 
Assu
med 
1118.3
76 
1 1118.37
6 
9.534 .007 
Gree
nhou
se-
Geiss
er 
1118.3
76 
1.000 1118.37
6 
9.534 .007 
Huyn
h-
Feldt 
1118.3
76 
1.000 1118.37
6 
9.534 .007 
Lowe
r-
boun
d 
1118.3
76 
1.000 1118.37
6 
9.534 .007 
HandgripDevice * 
Sex 
Spher
icity 
Assu
med 
322.34
2 
1 322.342 2.748 .116 
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Gree
nhou
se-
Geiss
er 
322.34
2 
1.000 322.342 2.748 .116 
Huyn
h-
Feldt 
322.34
2 
1.000 322.342 2.748 .116 
Lowe
r-
boun
d 
322.34
2 
1.000 322.342 2.748 .116 
HandgripDevice * 
Order_Starting_D
evice 
Spher
icity 
Assu
med 
380.52
3 
1 380.523 3.244 .089 
Gree
nhou
se-
Geiss
er 
380.52
3 
1.000 380.523 3.244 .089 
Huyn
h-
Feldt 
380.52
3 
1.000 380.523 3.244 .089 
Lowe
r-
boun
d 
380.52
3 
1.000 380.523 3.244 .089 
Error(HandgripDe
vice) 
Spher
icity 
Assu
med 
1994.1
89 
17 117.305 
  
Gree
nhou
se-
Geiss
er 
1994.1
89 
17.000 117.305 
  
Huyn
h-
Feldt 
1994.1
89 
17.000 117.305 
  
 133 
 
Lowe
r-
boun
d 
1994.1
89 
17.000 117.305 
  
Contraction Spher
icity 
Assu
med 
16105.
306 
3 5368.43
5 
1.293 .287 
Gree
nhou
se-
Geiss
er 
16105.
306 
1.172 13740.2
57 
1.293 .277 
Huyn
h-
Feldt 
16105.
306 
1.355 11888.1
95 
1.293 .281 
Lowe
r-
boun
d 
16105.
306 
1.000 16105.3
06 
1.293 .271 
Contraction * Sex Spher
icity 
Assu
med 
21521.
973 
3 7173.99
1 
1.728 .173 
Gree
nhou
se-
Geiss
er 
21521.
973 
1.172 18361.4
92 
1.728 .205 
Huyn
h-
Feldt 
21521.
973 
1.355 15886.5
30 
1.728 .204 
Lowe
r-
boun
d 
21521.
973 
1.000 21521.9
73 
1.728 .206 
Contraction * 
Order_Starting_D
evice 
Spher
icity 
Assu
med 
2697.3
29 
3 899.110 .217 .884 
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Gree
nhou
se-
Geiss
er 
2697.3
29 
1.172 2301.22
8 
.217 .685 
Huyn
h-
Feldt 
2697.3
29 
1.355 1991.04
4 
.217 .719 
Lowe
r-
boun
d 
2697.3
29 
1.000 2697.32
9 
.217 .648 
Error(Contraction
) 
Spher
icity 
Assu
med 
21167
9.029 
51 4150.56
9 
  
Gree
nhou
se-
Geiss
er 
21167
9.029 
19.926 10623.1
86 
  
Huyn
h-
Feldt 
21167
9.029 
23.030 9191.27
7   
Lowe
r-
boun
d 
21167
9.029 
17.000 12451.7
08 
  
HandgripDevice * 
Contraction 
Spher
icity 
Assu
med 
4026.5
11 
3 1342.17
0 
3.109 .034 
Gree
nhou
se-
Geiss
er 
4026.5
11 
1.233 3266.24
9 
3.109 .085 
Huyn
h-
Feldt 
4026.5
11 
1.437 2802.30
5 
3.109 .077 
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Lowe
r-
boun
d 
4026.5
11 
1.000 4026.51
1 
3.109 .096 
HandgripDevice * 
Contraction * Sex 
Spher
icity 
Assu
med 
2439.5
71 
3 813.190 1.884 .144 
Gree
nhou
se-
Geiss
er 
2439.5
71 
1.233 1978.94
6 
1.884 .184 
Huyn
h-
Feldt 
2439.5
71 
1.437 1697.85
3 
1.884 .180 
Lowe
r-
boun
d 
2439.5
71 
1.000 2439.57
1 
1.884 .188 
HandgripDevice * 
Contraction * 
Order_Starting_D
evice 
Spher
icity 
Assu
med 
524.05
9 
3 174.686 .405 .750 
Gree
nhou
se-
Geiss
er 
524.05
9 
1.233 425.109 .405 .574 
Huyn
h-
Feldt 
524.05
9 
1.437 364.726 .405 .604 
Lowe
r-
boun
d 
524.05
9 
1.000 524.059 .405 .533 
Error(HandgripDe
vice*Contraction) 
Spher
icity 
Assu
med 
22015.
025 
51 431.667 
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Gree
nhou
se-
Geiss
er 
22015.
025 
20.957 1050.48
7 
  
Huyn
h-
Feldt 
22015.
025 
24.427 901.274 
  
Lowe
r-
boun
d 
22015.
025 
17.000 1295.00
1 
  
 
 
 
7. FCU EMG (All Effects)  
Tests of Within-Subjects Effects 
Measure:   MEASURE_1   
Source 
Type III Sum 
of Squares df 
Mean 
Square F Sig. 
HandgripDevice Sphericity 
Assumed 
8681.593 1 8681.593 1.855 .191 
Greenhouse-
Geisser 
8681.593 1.000 8681.593 1.855 .191 
Huynh-Feldt 8681.593 1.000 8681.593 1.855 .191 
Lower-
bound 
8681.593 1.000 8681.593 1.855 .191 
HandgripDevice * Sex Sphericity 
Assumed 
9890.471 1 9890.471 2.114 .164 
Greenhouse-
Geisser 
9890.471 1.000 9890.471 2.114 .164 
Huynh-Feldt 9890.471 1.000 9890.471 2.114 .164 
Lower-
bound 
9890.471 1.000 9890.471 2.114 .164 
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HandgripDevice * 
Order_Starting_Device 
Sphericity 
Assumed 
488.073 1 488.073 .104 .751 
Greenhouse-
Geisser 
488.073 1.000 488.073 .104 .751 
Huynh-Feldt 488.073 1.000 488.073 .104 .751 
Lower-
bound 
488.073 1.000 488.073 .104 .751 
Error(HandgripDevice) Sphericity 
Assumed 
79546.582 17 4679.211 
  
Greenhouse-
Geisser 
79546.582 17.000 4679.211 
  
Huynh-Feldt 79546.582 17.000 4679.211   
Lower-
bound 
79546.582 17.000 4679.211 
  
Contraction Sphericity 
Assumed 
658080.224 3 219360.07
5 
1.318 .279 
Greenhouse-
Geisser 
658080.224 1.018 646511.62
0 
1.318 .268 
Huynh-Feldt 658080.224 1.149 572915.24
4 
1.318 .271 
Lower-
bound 
658080.224 1.000 658080.22
4 
1.318 .267 
Contraction * Sex Sphericity 
Assumed 
855364.706 3 285121.56
9 
1.713 .176 
Greenhouse-
Geisser 
855364.706 1.018 840327.97
4 
1.713 .208 
Huynh-Feldt 855364.706 1.149 744668.29
5 
1.713 .208 
Lower-
bound 
855364.706 1.000 855364.70
6 
1.713 .208 
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Contraction * 
Order_Starting_Device 
Sphericity 
Assumed 
51227.302 3 17075.767 .103 .958 
Greenhouse-
Geisser 
51227.302 1.018 50326.761 .103 .757 
Huynh-Feldt 51227.302 1.149 44597.758 .103 .787 
Lower-
bound 
51227.302 1.000 51227.302 .103 .753 
Error(Contraction) Sphericity 
Assumed 
8490232.970 51 166475.15
6 
  
Greenhouse-
Geisser 
8490232.970 17.304 490645.90
7 
  
Huynh-Feldt 8490232.970 19.527 434792.68
0 
  
Lower-
bound 
8490232.970 17.000 499425.46
9 
  
HandgripDevice * 
Contraction 
Sphericity 
Assumed 
47634.642 3 15878.214 .568 .639 
Greenhouse-
Geisser 
47634.642 1.056 45125.561 .568 .470 
Huynh-Feldt 47634.642 1.199 39739.636 .568 .490 
Lower-
bound 
47634.642 1.000 47634.642 .568 .461 
HandgripDevice * 
Contraction * Sex 
Sphericity 
Assumed 
91203.158 3 30401.053 1.088 .363 
Greenhouse-
Geisser 
91203.158 1.056 86399.174 1.088 .315 
Huynh-Feldt 91203.158 1.199 76087.070 1.088 .323 
Lower-
bound 
91203.158 1.000 91203.158 1.088 .312 
Sphericity 
Assumed 
7701.224 3 2567.075 .092 .964 
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HandgripDevice * 
Contraction * 
Order_Starting_Device 
Greenhouse-
Geisser 
7701.224 1.056 7295.574 .092 .779 
Huynh-Feldt 7701.224 1.199 6424.817 .092 .810 
Lower-
bound 
7701.224 1.000 7701.224 .092 .766 
Error(HandgripDevice*C
ontraction) 
Sphericity 
Assumed 
1425223.609 51 27945.561 
  
Greenhouse-
Geisser 
1425223.609 17.945 79420.716 
  
Huynh-Feldt 1425223.609 20.377 69941.521   
Lower-
bound 
1425223.609 17.000 83836.683 
  
 
8. TB EMG (All Effects)  
Tests of Within-Subjects Effects 
Measure:   MEASURE_1   
Source 
Type III Sum 
of Squares df 
Mean 
Square F Sig. 
HandgripDevice Sphericity 
Assumed 
266.707 1 266.707 .771 .393 
Greenhouse-
Geisser 
266.707 1.000 266.707 .771 .393 
Huynh-Feldt 266.707 1.000 266.707 .771 .393 
Lower-
bound 
266.707 1.000 266.707 .771 .393 
HandgripDevice * Sex Sphericity 
Assumed 
135.148 1 135.148 .391 .541 
Greenhouse-
Geisser 
135.148 1.000 135.148 .391 .541 
Huynh-Feldt 135.148 1.000 135.148 .391 .541 
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Lower-
bound 
135.148 1.000 135.148 .391 .541 
HandgripDevice * 
Order_Starting_Device 
Sphericity 
Assumed 
227.581 1 227.581 .658 .429 
Greenhouse-
Geisser 
227.581 1.000 227.581 .658 .429 
Huynh-Feldt 227.581 1.000 227.581 .658 .429 
Lower-
bound 
227.581 1.000 227.581 .658 .429 
Error(HandgripDevice) Sphericity 
Assumed 
5531.950 16 345.747 
  
Greenhouse-
Geisser 
5531.950 16.000 345.747 
  
Huynh-Feldt 5531.950 16.000 345.747   
Lower-
bound 
5531.950 16.000 345.747 
  
Contraction Sphericity 
Assumed 
6527.905 3 2175.968 .104 .958 
Greenhouse-
Geisser 
6527.905 1.501 4350.132 .104 .847 
Huynh-Feldt 6527.905 1.828 3570.127 .104 .886 
Lower-
bound 
6527.905 1.000 6527.905 .104 .752 
Contraction * Sex Sphericity 
Assumed 
82251.959 3 27417.320 1.305 .284 
Greenhouse-
Geisser 
82251.959 1.501 54811.901 1.305 .282 
Huynh-Feldt 82251.959 1.828 44983.788 1.305 .284 
Lower-
bound 
82251.959 1.000 82251.959 1.305 .270 
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Contraction * 
Order_Starting_Device 
Sphericity 
Assumed 
27750.028 3 9250.009 .440 .725 
Greenhouse-
Geisser 
27750.028 1.501 18492.347 .440 .593 
Huynh-Feldt 27750.028 1.828 15176.555 .440 .630 
Lower-
bound 
27750.028 1.000 27750.028 .440 .516 
Error(Contraction) Sphericity 
Assumed 
1008411.104 48 21008.565 
  
Greenhouse-
Geisser 
1008411.104 24.010 41999.706 
  
Huynh-Feldt 1008411.104 29.256 34468.899   
Lower-
bound 
1008411.104 16.000 63025.694 
  
HandgripDevice * 
Contraction 
Sphericity 
Assumed 
648.250 3 216.083 .196 .899 
Greenhouse-
Geisser 
648.250 1.846 351.130 .196 .806 
Huynh-Feldt 648.250 2.337 277.386 .196 .854 
Lower-
bound 
648.250 1.000 648.250 .196 .664 
HandgripDevice * 
Contraction * Sex 
Sphericity 
Assumed 
2219.143 3 739.714 .671 .574 
Greenhouse-
Geisser 
2219.143 1.846 1202.018 .671 .508 
Huynh-Feldt 2219.143 2.337 949.570 .671 .540 
Lower-
bound 
2219.143 1.000 2219.143 .671 .425 
Sphericity 
Assumed 
3753.857 3 1251.286 1.134 .345 
 142 
 
HandgripDevice * 
Contraction * 
Order_Starting_Device 
Greenhouse-
Geisser 
3753.857 1.846 2033.309 1.134 .331 
Huynh-Feldt 3753.857 2.337 1606.273 1.134 .339 
Lower-
bound 
3753.857 1.000 3753.857 1.134 .303 
Error(HandgripDevice*C
ontraction) 
Sphericity 
Assumed 
52947.537 48 1103.074 
  
Greenhouse-
Geisser 
52947.537 29.539 1792.468 
  
Huynh-Feldt 52947.537 37.392 1416.014   
Lower-
bound 
52947.537 16.000 3309.221 
  
 
9. RPE (All Effects)  
Tests of Within-Subjects Effects 
Measure:   MEASURE_1   
Source 
Type III Sum 
of Squares df 
Mean 
Square F Sig. 
Device Sphericity 
Assumed 
1.000 1 1.000 .332 .572 
Greenhouse-
Geisser 
1.000 1.000 1.000 .332 .572 
Huynh-Feldt 1.000 1.000 1.000 .332 .572 
Lower-
bound 
1.000 1.000 1.000 .332 .572 
Device * SEX Sphericity 
Assumed 
1.365 1 1.365 .454 .510 
Greenhouse-
Geisser 
1.365 1.000 1.365 .454 .510 
Huynh-Feldt 1.365 1.000 1.365 .454 .510 
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Lower-
bound 
1.365 1.000 1.365 .454 .510 
Device * 
Device_Starting_Order 
Sphericity 
Assumed 
12.804 1 12.804 4.256 .055 
Greenhouse-
Geisser 
12.804 1.000 12.804 4.256 .055 
Huynh-Feldt 12.804 1.000 12.804 4.256 .055 
Lower-
bound 
12.804 1.000 12.804 4.256 .055 
Error(Device) Sphericity 
Assumed 
51.148 17 3.009 
  
Greenhouse-
Geisser 
51.148 17.000 3.009 
  
Huynh-Feldt 51.148 17.000 3.009   
Lower-
bound 
51.148 17.000 3.009 
  
Contraction Sphericity 
Assumed 
32.322 3 10.774 10.195 .000 
Greenhouse-
Geisser 
32.322 1.678 19.259 10.195 .001 
Huynh-Feldt 32.322 2.060 15.688 10.195 .000 
Lower-
bound 
32.322 1.000 32.322 10.195 .005 
Contraction * SEX Sphericity 
Assumed 
16.947 3 5.649 5.346 .003 
Greenhouse-
Geisser 
16.947 1.678 10.098 5.346 .014 
Huynh-Feldt 16.947 2.060 8.226 5.346 .009 
Lower-
bound 
16.947 1.000 16.947 5.346 .034 
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Contraction * 
Device_Starting_Order 
Sphericity 
Assumed 
6.321 3 2.107 1.994 .127 
Greenhouse-
Geisser 
6.321 1.678 3.766 1.994 .160 
Huynh-Feldt 6.321 2.060 3.068 1.994 .150 
Lower-
bound 
6.321 1.000 6.321 1.994 .176 
Error(Contraction) Sphericity 
Assumed 
53.894 51 1.057 
  
Greenhouse-
Geisser 
53.894 28.531 1.889 
  
Huynh-Feldt 53.894 35.024 1.539   
Lower-
bound 
53.894 17.000 3.170 
  
Device * Contraction Sphericity 
Assumed 
1.377 3 .459 .500 .684 
Greenhouse-
Geisser 
1.377 1.753 .786 .500 .587 
Huynh-Feldt 1.377 2.168 .635 .500 .625 
Lower-
bound 
1.377 1.000 1.377 .500 .489 
Device * Contraction * 
SEX 
Sphericity 
Assumed 
.915 3 .305 .332 .802 
Greenhouse-
Geisser 
.915 1.753 .522 .332 .692 
Huynh-Feldt .915 2.168 .422 .332 .736 
Lower-
bound 
.915 1.000 .915 .332 .572 
Device * Contraction * 
Device_Starting_Order 
Sphericity 
Assumed 
2.794 3 .931 1.015 .394 
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Greenhouse-
Geisser 
2.794 1.753 1.594 1.015 .366 
Huynh-Feldt 2.794 2.168 1.289 1.015 .378 
Lower-
bound 
2.794 1.000 2.794 1.015 .328 
Error(Device*Contractio
n) 
Sphericity 
Assumed 
46.800 51 .918 
  
Greenhouse-
Geisser 
46.800 29.794 1.571 
  
Huynh-Feldt 46.800 36.851 1.270   
Lower-
bound 
46.800 17.000 2.753 
  
Sex* Contraction interaction 
 
Tests of Between-Subjects Effects 
Dependent Variable:   RPE   
Source 
Type III Sum of 
Squares df Mean Square F 
Corrected Model 171.265a 7 24.466 3.749 
Intercept 34953.340 1 34953.340 5355.699 
Gender 52.740 1 52.740 8.081 
Time 109.538 3 36.513 5.595 
Gender * Time 3.763 3 1.254 .192 
Error 992.010 152 6.526  
Total 36744.500 160   
Corrected Total 1163.275 159   
 
Tests of Between-Subjects Effects 
Dependent Variable:   RPE   
Source Sig. Partial Eta Squared Noncent. Parameter Observed Powerb 
Corrected Model .001 .147 26.242 .975 
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Intercept .000 .972 5355.699 1.000 
Gender .005 .050 8.081 .806 
Time .001 .099 16.784 .939 
Gender * Time .902 .004 .577 .085 
Error     
Total     
Corrected Total     
 
a. R Squared = .147 (Adjusted R Squared = .108) 
b. Computed using alpha = .05 
 
 
Multiple Comparisons 
Dependent Variable:   RPE   
Tukey HSD   
(I) Time (J) Time 
Mean Difference (I-
J) Std. Error Sig. 
Contraction 1 Contraction 2 -.8875 .57124 .408 
Contraction 3 -1.6500* .57124 .023 
Contraction 4 -2.2625* .57124 .001 
Contraction 2 Contraction 1 .8875 .57124 .408 
Contraction 3 -.7625 .57124 .542 
Contraction 4 -1.3750 .57124 .080 
Contraction 3 Contraction 1 1.6500* .57124 .023 
Contraction 2 .7625 .57124 .542 
Contraction 4 -.6125 .57124 .707 
Contraction 4 Contraction 1 2.2625* .57124 .001 
Contraction 2 1.3750 .57124 .080 
Contraction 3 .6125 .57124 .707 
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Multiple Comparisons 
Dependent Variable:   RPE   
Tukey HSD   
(I) Time (J) Time 
95% Confidence Interval 
Lower Bound Upper Bound 
Contraction 1 Contraction 2 -2.3714 .5964 
Contraction 3 -3.1339 -.1661 
Contraction 4 -3.7464 -.7786 
Contraction 2 Contraction 1 -.5964 2.3714 
Contraction 3 -2.2464 .7214 
Contraction 4 -2.8589 .1089 
Contraction 3 Contraction 1 .1661 3.1339 
Contraction 2 -.7214 2.2464 
Contraction 4 -2.0964 .8714 
Contraction 4 Contraction 1 .7786 3.7464 
Contraction 2 -.1089 2.8589 
Contraction 3 -.8714 2.0964 
 
Based on observed means. 
 The error term is Mean Square(Error) = 6.526. 
*. The mean difference is significant at the .05 level. 
 
 
10. NRS-Pain (All Effects)  
Tests of Within-Subjects Effects 
Measure:   MEASURE_1   
Source 
Type III Sum 
of Squares df 
Mean 
Square F Sig. 
Device Sphericity 
Assumed 
5.696 1 5.696 2.699 .119 
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Greenhouse-
Geisser 
5.696 1.000 5.696 2.699 .119 
Huynh-Feldt 5.696 1.000 5.696 2.699 .119 
Lower-
bound 
5.696 1.000 5.696 2.699 .119 
Device * SEX Sphericity 
Assumed 
.144 1 .144 .068 .797 
Greenhouse-
Geisser 
.144 1.000 .144 .068 .797 
Huynh-Feldt .144 1.000 .144 .068 .797 
Lower-
bound 
.144 1.000 .144 .068 .797 
Device * 
Device_Starting_Order 
Sphericity 
Assumed 
.681 1 .681 .323 .577 
Greenhouse-
Geisser 
.681 1.000 .681 .323 .577 
Huynh-Feldt .681 1.000 .681 .323 .577 
Lower-
bound 
.681 1.000 .681 .323 .577 
Error(Device) Sphericity 
Assumed 
35.870 17 2.110 
  
Greenhouse-
Geisser 
35.870 17.000 2.110 
  
Huynh-Feldt 35.870 17.000 2.110   
Lower-
bound 
35.870 17.000 2.110 
  
Contraction Sphericity 
Assumed 
1.206 3 .402 1.019 .392 
Greenhouse-
Geisser 
1.206 1.998 .603 1.019 .372 
Huynh-Feldt 1.206 2.531 .476 1.019 .384 
Lower-
bound 
1.206 1.000 1.206 1.019 .327 
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Contraction * SEX Sphericity 
Assumed 
.285 3 .095 .241 .868 
Greenhouse-
Geisser 
.285 1.998 .143 .241 .787 
Huynh-Feldt .285 2.531 .113 .241 .836 
Lower-
bound 
.285 1.000 .285 .241 .630 
Contraction * 
Device_Starting_Order 
Sphericity 
Assumed 
2.243 3 .748 1.895 .142 
Greenhouse-
Geisser 
2.243 1.998 1.123 1.895 .166 
Huynh-Feldt 2.243 2.531 .886 1.895 .153 
Lower-
bound 
2.243 1.000 2.243 1.895 .186 
Error(Contraction) Sphericity 
Assumed 
20.120 51 .395 
  
Greenhouse-
Geisser 
20.120 33.969 .592 
  
Huynh-Feldt 20.120 43.019 .468   
Lower-
bound 
20.120 17.000 1.184 
  
Device * Contraction Sphericity 
Assumed 
.977 3 .326 1.212 .315 
Greenhouse-
Geisser 
.977 2.448 .399 1.212 .313 
Huynh-Feldt .977 3.000 .326 1.212 .315 
Lower-
bound 
.977 1.000 .977 1.212 .286 
Device * Contraction * 
SEX 
Sphericity 
Assumed 
1.380 3 .460 1.711 .176 
Greenhouse-
Geisser 
1.380 2.448 .564 1.711 .187 
Huynh-Feldt 1.380 3.000 .460 1.711 .176 
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Lower-
bound 
1.380 1.000 1.380 1.711 .208 
Device * Contraction * 
Device_Starting_Order 
Sphericity 
Assumed 
.707 3 .236 .877 .459 
Greenhouse-
Geisser 
.707 2.448 .289 .877 .443 
Huynh-Feldt .707 3.000 .236 .877 .459 
Lower-
bound 
.707 1.000 .707 .877 .362 
Error(Device*Contractio
n) 
Sphericity 
Assumed 
13.707 51 .269 
  
Greenhouse-
Geisser 
13.707 41.615 .329 
  
Huynh-Feldt 13.707 51.000 .269   
Lower-
bound 
13.707 17.000 .806 
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